# Orm v. Secretary of Health and Human Services

> United States Court of Federal Claims · April 18, 2023

URL: https://www.frixlaw.com/law-library/cases/9387491

## Case

- **Court:** United States Court of Federal Claims
- **Decided:** April 18, 2023
- **Precedential status:** Published
- **Opinion:** Opinion
- **Judges:** Nora Beth Dorsey
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/9387491

## How later opinions describe it (automated extraction)

- noting that “close calls” are resolved in Petitioner’s favor
- noting that special masters are bound by both § 13(b)(1) and Vaccine Rule 8(b)(1) to consider only evidence that is both “relevant” and “reliable”

## Opinion text

In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
Filed: March 24, 2023

* * * * * * * * * * * * * * *
AUTUMN ORM, * PUBLISHED
*
Petitioner, * No. 14-257V
*
v. * Special Master Nora Beth Dorsey
*
SECRETARY OF HEALTH * Entitlement; Human Papillomavirus
AND HUMAN SERVICES, * (“HPV”) Vaccine; Celiac Disease.
*
Respondent. *
*
* * * * * * * * * * * * * * *

Mark Theodore Sadaka, Law Offices of Sadaka Associates, LLC, Englewood, NJ, for Petitioner.
Debra A. Filteau Begley, U.S. Department of Justice, Washington, DC, for Respondent.

DECISION 1

I. INTRODUCTION

On April 2, 2014, Autumn Orm (“Petitioner”) 2 filed a petition under the National
Vaccine Injury Compensation Program (“Vaccine Act” or “the Program”), 42 U.S.C. § 300aa-10

1
Because this Decision contains a reasoned explanation for the action in this case, the
undersigned is required to post it on the United States Court of Federal Claims’ website in
accordance with the E-Government Act of 2002. 44 U.S.C. § 3501 note (2012) (Federal
Management and Promotion of Electronic Government Services). This means the Decision will
be available to anyone with access to the Internet. In accordance with Vaccine Rule 18(b),
Petitioner has 14 days to identify and move to redact medical or other information, the disclosure
of which would constitute an unwarranted invasion of privacy. If, upon review, the undersigned
agrees that the identified material fits within this definition, the undersigned will redact such
material from public access.
2
The petition was originally filed by Theodore and Jodi Orm, as parents of Autumn Orm.
Petition (ECF No. 1). On November 9, 2015, the case caption was amended to Autumn Orm
because she reached the age of majority. Order dated Nov. 9, 2015 (ECF No. 60).

1
et seq. (2012) 3 alleging that as a result of human papillomavirus (“HPV”) vaccines (Gardasil)
she received on August 30, 2011 and November 22, 2011, she suffers from celiac disease. 4
Amended (“Am.”) Petition at Preamble (ECF No. 172); Joint Submission, filed May 23, 2022, at
1 (ECF No. 296).

After carefully analyzing and weighing the evidence presented in this case, in accordance
with the applicable legal standards, the undersigned finds Petitioner has failed to provide
preponderant evidence that the HPV vaccines she received caused her to develop celiac disease.
Thus, Petitioner has failed to satisfy her burden of proof under Althen v. Secretary of Health &
Human Services, 418 F.3d 1274, 1280 (Fed. Cir. 2005). Therefore, the petition must be
dismissed.

II. ISSUES TO BE DECIDED

The parties agree that Petitioner suffers from celiac disease but disagree as to the onset of
her illness. Joint Submission at 1. They also disagree about whether the HPV vaccinations can
or did cause Petitioner’s celiac disease 5 and dispute all three Althen prongs. Id.

III. PROCEDURAL HISTORY

This case has a lengthy procedural history. Petitioner initially alleged that she suffered
bilateral leg weakness and myasthenia gravis as a result of her HPV vaccinations. Petition at
Preamble (ECF No. 1). Subsequently, she filed an amended petition, in which she alleged that
she suffered “numerous autoimmune diseases including: Celiac Disease, Postural Orthostatic
Tachycardia Syndrome (“POTS”), Chronic Fatigue Syndrome (“CFS”), Small Fiber Neuropathy,
in addition to others,” which she alleged were caused by her HPV vaccinations on August 30,
2011 and November 22, 2011. Am. Petition at Preamble.

3
The National Vaccine Injury Compensation Program is set forth in Part 2 of the National
Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended,
42 U.S.C. §§ 300aa-10 to -34 (2012). All citations in this Decision to individual sections of the
Vaccine Act are to 42 U.S.C. § 300aa.
4
Petitioner initially alleged that she suffered from bilateral leg weakness and myasthenia gravis,
and subsequently asserted that she suffered from celiac disease, Postural Orthostatic Tachycardia
Syndrome (“POTS”), Chronic Fatigue Syndrome (“CFS”), Small Fiber Neuropathy, and other
autoimmune diseases. Petition at Preamble (ECF No. 1); Amended (“Am.”) Petition at Preamble
(ECF No. 172). In her joint submission, however, Petitioner narrowed the issues and confirmed
celiac disease as her alleged vaccine-related illness. Joint Submission, filed May 23, 2022, at 1
(ECF No. 296).
5
In her supportive brief, Petitioner took the position that “the development of celiac disease as a
result of Gardasil [HPV vaccine] led to the development of additional autoimmune disease.”
Petitioner’s Brief (“Pet. Br.”), filed May 7, 2021, at 6 (ECF No. 265). Since the undersigned
finds that Petitioner has failed to prove causation by preponderant evidence, she does not reach
the question of whether Petitioner’s celiac disease caused or contributed to other illnesses.

2
The parties filed numerous expert reports and medical literature during the course of
litigation. This case was assigned to the undersigned on December 8, 2021. Notice of
Reassignment dated Dec. 8, 2021 (ECF No. 285). Subsequently, the parties filed a joint
submission to clarify Petitioner’s vaccine-related injury. Joint Submission. During a status
conference on June 8, 2022, the undersigned asked the parties to consider settlement
negotiations. Order dated June 8, 2022, at 1 (ECF No. 297). On July 1, 2022, Petitioner filed a
status report stating her preference to “resolve this case through a ruling on the record.”
Petitioner’s (“Pet.”) Joint Status Report (“Rept.”), filed July 1, 2022 (ECF No. 300).
Subsequently, in a status report dated November 10, 2022, Respondent “reviewed [P]etitioner’s
demand and determined that he would like to continue with litigation.” Respondent’s (“Resp.”)
Status Rept., filed Nov. 10, 2022 (ECF No. 309). Respondent also requested that the
undersigned issue a ruling on the record. Id.

This matter is now ripe for adjudication.

IV. MEDICAL TERMINOLOGY 6

Celiac disease is “a life-long autoimmune condition mainly involving the proximal small
intestine of genetically susceptible individuals.” Pet. Exhibit (“Ex.”) 88 at 14. Gluten, defined
as a “storage protein of wheat,” along with similar proteins in barley and rye, are the “offending
inducers” of the illness. Id. “Tissue transglutaminase (tTg)[7] is the auto-antigen against which
the abnormal immune response is directed [] and the [immunoglobulin A (“IgA”)]-anti-tTg is the
most used serological marker[] to diagnose the disease.” Id. Iron deficiency anemia, caused by
nutritional deficiency, is a known complication of the illness. Id. Historically, the “classic
picture” of celiac disease included the triad of malnutrition, chronic diarrhea, and abdominal
pain. Id.

The disease is triggered by ingestion of gluten, a protein present in wheat, and other
grains such as barley and rye. Resp. Ex. T at 4. When a person with celiac disease eats gluten,
the protein in it damages the surface of the intestine, or the villi, which are “small finger-like
projections along the wall of the small intestine.” Id. When the villi are damaged, the intestine
is unable to absorb nutrients when eating. Id. This may cause malnourishment, weight loss,
diarrhea, bleeding, and abdominal pain. Id. Other symptoms of celiac disease may include
anemia, rash, headaches, fatigue, bone and joint pain, osteoporosis, mouth ulcers, and heartburn.
Id.

Diagnosis is made by obtaining blood tests, including anti-tTG antibody and anti-
endomysial antibody (“EMA”) testing, as well as endoscopy with biopsy to determine whether

6
The medical terminology is taken from expert reports submitted by Petitioner’s expert, Dr.
Aaron Lerner, and Respondent’s expert, Dr. Chris A. Liacouras. See Pet. Exhibit (“Ex.”) 88;
Resp. Ex. T.
7
In some medical records, expert reports, and medical articles, this antibody is also abbreviated
as TTG. The undersigned will use the abbreviation tTG throughout this Decision.

3
abnormalities of the lining of the intestine, as described above, exist. Resp. Ex. T at 4.
Treatment is adherence to a life-time gluten-free diet. Id.

V. FACTUAL SUMMARY

A. Summary of Medical Records 8

Petitioner was born on November 4, 1997. Pet. Ex. 1. Her medical history prior to the
vaccinations at issue is unremarkable. Pet. Ex. 12 at 5-11. At her well-child visit to her
pediatrician on November 1, 2010, she was assessed as a well child, although she was noted to
have scoliosis. Id. at 4. At that visit, Petitioner received influenza and hepatitis A vaccinations.
Id. at 55; Pet. Ex. 2 at 2. There is no evidence of any adverse reaction to those vaccinations.

On August 30, 2011, Petitioner saw her primary care doctor, Dr. Paula Dekeyser, D.O.,
for an evaluation of hip pain, specifically over the iliac crest, that occurred while running. Pet.
Ex. 12 at 2. Dr. Dekeyser’s history notes that Petitioner was in cross-country, and “ha[d] been
running a lot since the first part of August . . . [and] has felt pain in her hips.” Id. Assessment
was “bilateral iliac crest pain, probably musculoskeletal.” Id. (emphasis omitted). Petitioner
received her first HPV vaccine at that visit. Id. Petitioner received her second HPV vaccine on
November 22, 2011. Id. at 1.

Moving forward to 2012, on January 5, 2012, Petitioner presented to Dr. Dekeyser with
“shortness of breath” that occurred during exercise “for a couple months,” which made it “very
difficult” for her to participate in cross-country and basketball. Pet. Ex. 14 at 3. During her last
basketball game, she had “burning in her chest.” Id. She also complained of diarrhea,
“intermittent abdominal pain,” and weight loss. Id. On physical examination, Petitioner
appeared very pale and she had some abdominal tenderness. Id. Complete blood count (“CBC”)
revealed “profound anemia at 8.7.” 9 Id.

A referral was made to gastroenterologist, Dr. Sachin S. Kunde, who Petitioner saw on
January 10, 2012. Pet. Ex. 4 at 17; Pet. Ex. 65 at 14. Dr. Kunde’s history stated,

[Petitioner] is a 14-year-old . . . who presents here with chronic diarrhea, weight
loss, and anemia. [Petitioner] was healthy until the summer of 2011, when she
started noticing tiredness. She started cross-country running and she started
feeling very tired even when she was not running at that time. Later, this was
followed by loss of weight. She has lost approximately 6 pounds of weight in the
last 2 months. She started noticing that she was having loose stools in the last 2 to
3 months. . . . She generally gets upper crampy abdominal pain in the middle of

8
Petitioner filed numerous medical records, many of which relate to other diagnoses and medical
care that is not related to the diagnosis of, or care and treatment of, her celiac disease. For the
sake of clarity and brevity, this medical summary covers only Petitioner’s care and treatment
related to celiac disease.
9
Petitioner’s hemoglobin was 8.7 gm/dL (normal range 12.0-14.5 gm/dL). Pet. Ex. 12 at 20.

4
the night and she has to go to the bathroom. She has never seen blood in the
stool, but her workup . . . showed . . . anemia. She does not have any joint pain,
but she complains of her bones aching.

Pet. Ex. 4 at 19. Family history was significant for Crohn’s disease 10 and gastrointestinal
disease. Id. at 17.

Laboratory studies revealed positive Hemoccult tests. 11 Pet. Ex. 4 at 19; Pet. Ex. 12 at
18. Hemoglobin had decreased to 7.7 “at the lowest.” Pet. Ex. 4 at 19; see also Pet. Ex. 12 at 18.
Petitioner’s mean corpuscular volume (“MCV”) 12 was low at 66.5 (normal range 79.9-92.3 fL).
Pet. Ex. 12 at 15. Petitioner also had decreased iron levels at 9 (normal range 40-150 mcg/dl)
and low ferritin 13 at 2.7 (normal range 11-307 ng/mL). Pet. Ex. 4 at 19; Pet. Ex. 12 at 16. The
positive Hemoccult tests, indicating blood in the stool, along with weight loss, tiredness, and iron
deficiency due to blood loss, led Dr. Kunde to consider differential diagnosis of infectious or
inflammatory colitis, specifically Crohn’s disease. Pet. Ex. 4 at 19. Additional diagnostic tests
were ordered, including upper endoscopy and colonoscopy. Id. Petitioner was also referred to
hematology. Id.

Laboratory studies performed on January 11, 2012 were significant for an elevated tTG
IgA antibody of 150 (normal < 19 U/mL). 14 Pet. Ex. 4 at 11. Endoscopy and colonoscopy done

10
Crohn’s disease is an inflammatory bowel disease of the gastrointestinal tract. Crohn Disease,
Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=
70226 (last visited Feb. 23, 2023).
11
Hemoccult, or guaiac test, tests for occult blood, which is “blood present in such small
quantities that it is not visible to the naked eye and can be detected only by chemical tests of
suspected material,” such as feces. Hemoccult, Dorland’s Med. Dictionary Online,
https://www.dorlandsonline.com/dorland/definition?id=21983 (last visited Feb. 23, 2023);
Occult Blood, Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/dorland/
definition?id=60877 (last visited Feb. 23, 2023).
12
Mean corpuscular volume (“MCV”) is “the average volume of erythrocytes,” which are
“elements found in peripheral blood.” Mean Corpuscular Volume, Dorland’s Med. Dictionary
Online, https://www.dorlandsonline.com/dorland/definition?id=118634 (last visited Feb. 23,
2023); Erythrocyte, Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/
dorland/definition?id=17213 (last visited Feb. 23, 2023).
13
Ferritin is a “form[] in which iron is stored in the body.” Ferritin, Dorland’s Med. Dictionary
Online, https://www.dorlandsonline.com/dorland/definition?id=18386 (last visited Feb. 23,
2023).
14
For a list of all of Petitioner’s tTG results, see Pet. Ex. 88 at 13. EMA testing was
recommended for further evaluation or for confirmation where clinically indicated. Pet. Ex. 4 at
11. However, the results of this testing, if done, do not appear to be in the records.

5
January 11, 2012 revealed numerous abnormalities including villous 15 alteration, focal active
duodenitis, and erosion in the duodenum; mild chronic gastritis in the stomach; mild focal active
colitis in the cecum; and focal active colitis in the ascending, transverse, descending, and rectal
sigmoid colon. 16 Id. at 13. The pathologist noted that “[i]n the absence of an infectious etiology,
inflammatory bowel disease [was] a consideration, although the biopsies [did] not show marked
chronic injury.” Id. Microscopic examination showed the following:

A. Duodenal mucosa features severe villous alteration and effacement with mild
intraepithehal lymphocytosis. The lamina propria contains a dense
lymphoplasmacytic infiltrate. Eosinophils are increased at 20-50+ per high power
field. Neutrophils are sprinkled throughout and are active in the surface
epithelium and focally forming active cryptitis without crypt abscesses.
Granulomas or parasites are not identified. There is crypt hyperplasia. There is
some crypt distortion.

B. Gastric antral and fundic type mucosa features relatively intact foveolar and
glandular epithelium. The lamina propria contains a light lymphoplasmocytic
infiltrate. Eosinophils number less than 20 per high power field. In neutrophils
are sparse, but focally active on one fragment. Granulomas are not identified.
Helicobacter pylori type organisms are not identified on routine stain; a properly
controlled immunohistochemical stain is negative.

C. Esophageal squamous mucosa features no significant basal cell hyperplasia or
spongiosis. Lymphocytes are sparse.

D. Terminal ileum biopsies feature intact villous architecture with focal
prominent lymphoid nodularity. The lamina propria contains the usual mixture of
lymphocytes and plasma cells with eosinophils increased at 20-60 per high power
field. Significant neutrophilic inflammation or granulomas are not identified.

E.-1. Cecal, colonic, and rectosigmoid biopsies are similar and feature relatively
intact surface epithelium with minimal crypt distortion. The lamina propria
contains the usual mixture of inflammatory cells. Eosinophilia is prominent at
50+ per high power field. All of the biopsies feature some degree of focal active
cryptitis without crypt abscesses or granulomas.

Id. at 15.

15
Villous means “shaggy with soft hairs; covered with villi.” Villose, Dorland’s Med.
Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=53144 (last visited
Feb. 23, 2023).
16
For a discussion of biopsy changes seen in celiac disease, see Pet. Ex. 103 at 2 (Hugh J.
Freeman, Pearls and Pitfalls in the Diagnosis of Adult Celiac Disease, 22 Can. J.
Gastroenterology 273 (2008)).

6
Dr. Kunde spoke with Petitioner’s family about the pathology results and the positive
tTG IgA antibody results and diagnosed Petitioner with celiac disease on January 16, 2012. Pet.
Ex. 65 at 39. Follow-up blood work showed improved hemoglobin (12.1). Id. at 41. On
February 22, 2012, the hemoglobin and iron results showed continued improvement, and the plan
was to continue a gluten-free diet and iron supplements. Id. at 50. Petitioner continued to have
follow-up lab studies, and in April 2012, her hemoglobin was normal at 12.3. Id. at 56. Her
ferritin remained low at 10. Id.

On July 25, 2012, Petitioner’s mother call Dr. Kunde’s office reporting that Petitioner
had shortness of breath, leg pains, and extreme lack of energy for one week. Pet. Ex. 65 at 67.
Labs showed that her iron level was less than 10 (low). Id. Additional lab studies were ordered.
Id. In a follow-up call on August 3, 2012, Petitioner’s mother explained that Petitioner was
“tired, exhausted, [and] depressed.” Id. at 63. Due to participation in sports, and travel for
sports, Petitioner was eating at fast food restaurants and having “a very difficult time with her
[celiac disease diagnosis].” Id. Petitioner’s mother also expressed concerns that Petitioner had
depression and was interested in a support group or counseling. Id. Information was provided to
the family, and a social worker was contacted to assist with these concerns. Id. at 62. On
August 3, 2012, Petitioner’s tTG IgA was elevated, and Dr. Kunde opined that Petitioner’s celiac
disease was “not controlled well.” Id. at 63.

Labs drawn September 4, 2012 showed normal hemoglobin (12.8) and iron (88.00) levels
and an elevated tTG IgA (9.8; normal < 4.0 U/mL). Pet. Ex. 9 at 21-22; Pet. Ex. 65 at 91-92.
Petitioner and her family met with a registered dietician on October 11, 2012, for education on
gluten-free diet. Pet. Ex. 65 at 101. Petitioner continued to have difficulty with her gluten-free
diet while traveling for sports. Id. She saw Dr. Kunde’s nurse practitioner for a follow-up on
October 11, 2012. Id. At that visit, Petitioner reported that she was taking her iron supplement,
following a gluten-free diet, playing basketball, and running track. Id. at 101-02. She reported
abdominal symptoms only with gluten ingestion. Id. at 102. On December 20, 2012,
Petitioner’s tTG IgA result was “improved and near normal” at 5.9. Id. at 123-25; see also Pet.
Ex. 9 at 26. Dr. Kunde planned to repeat testing in six months. Pet. Ex. 65 at 125.

Dr. Dekeyser saw Petitioner for follow-up on February 11, 2013. Pet. Ex. 5 at 125.
Petitioner complained of “pain in her upper legs, over quad[riceps] and [shortness of breath] with
exertion. Her total [iron] was 39 down from 85 in December.” Pet. Ex. 65 at 127. On February
14, 2013, Petitioner’s labs revealed positive antinuclear antibodies (“ANA”) 17 at 1:640. Pet. Ex.
5 at 152. Dr. Kunde spoke with Petitioner’s mother on February 20, 2013 to report that the tTG
IgA was “mildly elevated but improved compared to [time of] diagnosis (150 vs. 31).” Pet. Ex.
65 at 142. The other labs, iron and hemoglobin, were normal. Id. Dr. Kunde recommended
stool studies, and if positive, they would consider endoscopy studies. Id. Petitioner’s stool

17
Antinuclear antibodies (“ANA”) are “antibodies directed against nuclear antigens; ones
against a variety of different antigens are almost invariably found in systemic lupus
erythematosus and are frequently found in rheumatoid arthritis, scleroderma (systemic sclerosis),
Sjögren syndrome, and mixed connective tissue disease.” Antinuclear Antibodies, Dorland’s
Med. Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=56804 (last
visited Feb. 23, 2023). For a list of all of Petitioner’s ANA results, see Pet. Ex. 88 at 13.

7
studies were negative (did not show bleeding) but she continued to have diarrhea, and was weak
and short of breath on exertion. Id. at 143. Dr. Kunde recommended endoscopy and
colonoscopy. Id.

In 2013 and 2014, Petitioner underwent extensive diagnostic testing and treatment with
intravenous immune globulin (“IVIG”) infusions for ongoing issues with weakness and she saw
numerous specialists, including neurology, neuromuscular, psychiatry, cardiology, pulmonology,
and genetics, at the University of Michigan. See Pet. Exs. 149(a)-(c). These specialists did not
provide specific care or treatment relative to Petitioner’s celiac disease.

In 2017, Petitioner was seen by immunologist, Dr. Jill Schofield. See Pet. Ex. 202. On
August 30, 2017, Petitioner’s tTG IgA level was 7 (normal range 0-3), interpreted as weakly
positive. Id. at 22. Dr. Schofield noted that “[t]here [was] suspicion that [Petitioner] [was] being
exposed to hidden sources of gluten given persistently positive anti-[tTG].” Id. at 29.

On December 19, 2019, now age 22, Petitioner saw Dr. Michael David Rice at the
Michigan Medicine Gastroenterology Clinic to establish care for her celiac disease. Pet. Ex. 335
at 9, 11. She reported a past medical history of “antiphospholipid antibody syndrome, Sjogren
syndrome, [POTS], mast cell activation syndrome, history of [pulmonary embolus] on chronic
anticoagulation therapy, and celiac disease.” Id. at 11. Petitioner reported that she kept a gluten-
free diet and since doing so, “many of her symptoms significantly improved.” Id. at 12. Dr.
Rice recommended updated labs, endoscopy and colonoscopy studies, and a referral to nutrition
services. Id. at 16-17. Blood work revealed Petitioner’s tTG IgA was 66 (normal < 15 U/mL).
Id. at 52. Her iron level was low and oral iron replacement was recommended. Id. at 77.
Computerized tomography (“CT”) showed a “few prominent thickened loops of proximal small
bowel/jejunum,” consistent with her history of celiac disease. Id. at 67. Upper endoscopy and
colonoscopy performed on February 25, 2020 revealed no abnormalities. Id. at 106-07. Biopsies
taken during these studies were also normal. Id. at 167. Capsule endoscopy done the same date
showed normal small bowel and no changes to suggest that she had complications from her
celiac disease. Id. at 142-43.

Follow-up with Dr. Rice occurred virtually on May 13, 2020. Pet. Ex. 335 at 176. She
reported being more vigilant with her gluten-free diet and her bowel movement pattern had
improved. Id. Follow-up was recommended in six months. Id. at 182. Petitioner’s virtual visit
with Dr. Rice was scheduled for January 28, 2021, however, it is not clear from the records
whether Dr. Rice saw Petitioner for that appointment. Id. at 194-97.

No additional records related to Petitioner’s celiac disease have been filed.

8
B. Hearing Testimony, Declarations, and Affidavits 18

1. Affidavit and Testimony of Petitioner 19

Petitioner executed an affidavit on September 12, 2016, at the age of 18, describing her
participation in sports from 2010 through 2013. Pet. Ex. 60. She explained that in the eighth
grade, from August 2010 to June 2011, she ran cross-country and track and played basketball.
Id. at ¶¶ 3-4. During this school year, she did not have any physical conditions that affected her
ability to play at her “maximum ability.” Id. at ¶ 6. This remained true for the summer of 2011.
Id. at ¶ 8. On August 30, 2011, she received her first HPV vaccine. Id. at ¶ 10. After reviewing
her medical records from that date, she recalled telling her doctor that she had hip pain while
running. Id. (citing Pet. Ex. 66). Petitioner recalled that at a cross-country meet on September
10, 2011, she had “pain in both of [her] legs and [her] entire body was weak and [she] had
difficulty breathing.” Id. at ¶ 11. “This was the first time that [Petitioner] experienced anything
like this.” Id. After this, she continued to have similar problems during practices and meets. Id.
at ¶ 14. She also developed “excruciating pain in [her] chest” as well as leg pain that occurred
the last meet of her freshman year. Id. at ¶ 15. Petitioner continued to experience weakness,
pain in her legs, difficulty breathing, and fatigue in November and December 2011. Id. at ¶¶ 16-
18. During a basketball practice on December 29, 2011, Petitioner felt that she could not
breathe, and “[her] lungs felt like they were ‘on fire.’” Id. at ¶ 18. This event precipitated an
appointment with Petitioner’s physician, Dr. Dekeyser, on January 5, 2012. Id. at ¶ 20.

In addition to her affidavit, Petitioner also testified at a hearing in this matter on
September 16, 2016. Transcript (“Tr.”) 3. Her testimony was consistent with her affidavit,
summarized above. She testified that she did not begin to have any physical problems until a
cross-country meet on September 10, 2011. Tr. 29-30. On that date, she “could barely breathe,”
she felt “very weak,” and her “legs were like achy, almost.” Tr. 30-31. By the cross-country
meet on October 15, 2011, Petitioner realized that “something was majorly wrong.” Tr. 32. Her
symptoms had increased, she “couldn’t breathe,” and she had “a burning sensation in [her] legs.”
Id. From that time until her second HPV vaccination, Petitioner experienced “major fatigue.”
Tr. 37.

Moving forward, Petitioner explained that on December 29, 2011, she had practice for
varsity basketball. Tr. 41. Prior to practice, she had begun to notice that when she walked
upstairs, she had shortness of breath, and she had begun “seeing like a fading in [] [her] eyes.”

18
Several other exhibits were filed by Petitioner, including documents from her Facebook page
from 2010 through 2013, and documents from her mother’s Facebook page for the same period.
See Pet. Exs. 51-59. Copies of emails between Petitioner’s mother and Petitioner’s physicians
were filed. See Pet. Ex. 62. Various articles, including several about Petitioner, phone records,
and basketball and track schedules, were also filed. See Pet. Exs. 72-76. The undersigned has
reviewed these documents but did not find them relevant to the issues in dispute, and therefore,
they are not summarized herein.
19
Although Petitioner’s affidavit covers 2010 until 2013, the undersigned summarizes only the
portions relevant to the issue of onset of her celiac disease.

9
Id. During basketball practice, she was not able to keep up with the other players, and her “lungs
were literally burning as if they were on fire, almost. It was worse than before” and she “could
barely breathe.” Id. She told her mother about her problems, and her mother made an
appointment for Petitioner to see her physician, Dr. Dekeyser on January 5, 2012. Tr. 42, 44.
After testing, Petitioner learned that she had celiac disease. Tr. 45.

2. Affidavit and Testimony of Petitioner’s Mother, Jodi Orm

Petitioner’s mother, Jodi Orm, executed an affidavit on April 7, 2014, describing the
onset of her daughter’s illness. She averred that Petitioner complained of “shortness of breath
and weak legs” during cross-country meets on September 10, September 17, and October 4,
2011. Pet. Ex. 3 at ¶¶ 4-6. She further averred that Petitioner did not have these symptoms
before she received the HPV vaccine on August 30, 2011. Id. at ¶ 16.

Ms. Orm filed another affidavit, executed September 12, 2016, in which she summarized
the events that occurred relative to Petitioner’s health beginning in the summer of 2011. Pet. Ex.
61. Notably, Ms. Orm has a Master of Science in Nursing and is a Nursing Education
Consultant. Id. at ¶ 1. She averred that prior to September 2011, her daughter was healthy and a
talented athlete who excelled at sports. Id. at ¶ 3. Although Petitioner had hip pain in August
2011, it was not viewed as a serious condition, but attributed to cross-country running. Id. at ¶ 5.
Ms. Orm recalled that at the cross-country meet on September 10, 2011, Petitioner was out of
breath and weak. Id. at ¶ 6. Petitioner complained of leg weakness and soreness, which
continued throughout the season. Id. at ¶¶ 6-9. In early January 2012, Petitioner was diagnosed
with iron deficiency and celiac disease. Id. at ¶ 12. The remainder of Ms. Orm’s affidavit dealt
with the course of Petitioner’s celiac disease, as well as her work up for other medical conditions
not relevant to the issues here.

Like Petitioner, Ms. Orm testified at the hearing on September 16, 2016, and her
testimony was consistent with her affidavits. Ms. Orm testified about the September 10, 2011
meet and recalled that Petitioner said that her “legs felt weird” and she was “short of breath.” Tr.
156. Ms. Orm also recalled the events of December 29, 2011, particularly that Petitioner was
“sobbing” and “very short of breath.” Tr. 159. Ms. Orm made an appointment for Petitioner to
see Dr. Dekeyser. Tr. 160. Ultimately, they learned that Petitioner had iron deficiency and
celiac disease. Tr. 161. Ms. Orm explained that she did not seek medical care for Petitioner in
September 2011 when she had shortness of breath during the cross-country meet because the
symptoms went away. Tr. 210. The symptoms were “milder in the beginning” and “episodic”
and then they “would go away.” Tr. 210-11.

3. Statements and Affidavits from Petitioner’s Coaches 20

Petitioner’s former coach Mandi Johnson submitted an email on October 16, 2014 and an
affidavit executed on July 19, 2016, describing the decline in Petitioner’s performance during

20
Petitioner’s cross-country schedules for 2010 and 2011 and her basketball schedule for 2011-
2012 were filed. See Pet. Ex. 47 (cross-country 2011); Pet. Ex. 49 (basketball); Pet. Ex. 50
(cross-country 2010).

10
track and basketball her freshman (2011-2012) and sophomore years (2012-2013) of high school
as compared to prior years (2008-2010). Pet. Exs. 16, 41. Ms. Johnson specifically noticed that
Petitioner was behind the other runners her freshman year. Pet. Ex. 16 at 1. When Petitioner
began basketball that November, she was “very short winded” and was no longer one of the
fastest players on the team. Id. Coach Johnson also described Petitioner’s decline during the
basketball season beginning in 2011 through the following season ending in 2013. Pet. Ex. 41 at
¶¶ 6-12.

Coach Doug Ingalls sent an email dated October 21, 2014 and executed an affidavit July
18, 2016 stating that in the seventh grade and summer basketball, from 2009 to the summer of
2010, Petitioner “could run all day.” Pet. Ex. 17 at 1; see also Pet. Ex. 42 at ¶¶ 1-4. During this
time frame, Petitioner never became tired during games and “had virtually, no physical limits.”
Pet. Ex. 42 at 1. He did not observe Petitioner during her freshman year (2011-2012). Pet. Ex.
17 at 1; Pet. Ex. 42 at ¶ 5. In her sophomore year (2012-2013), Mr. Ingalls was “shocked” when
he saw that Petitioner could “only run or play 20 to 30 seconds at a time.” Pet. Ex. 17 at 1; see
also Pet. Ex. 42 at ¶ 5.

Coach Dorene Ingalls wrote a letter emailed on October 21, 2014 and executed an
affidavit on July 18, 2016, describing the difference she observed in Petitioner’s athletic abilities
from elementary school through junior high and high school. Pet. Exs. 19, 43. Ms. Ingalls noted
that Petitioner did not run well her freshman year (2011-2012), and when she began basketball,
she was unable to participate in “more than a few minutes of intense workout.” Pet. Ex. 19 at 2;
see also Pet. Ex. 43 at ¶¶ 3-5.

Emily Fullerton, Petitioner’s Physical Education teacher and cross-country coach,
submitted an email October 19, 2014 as well as an affidavit executed July 19, 2016, with
Petitioner’s cross-country times from eighth grade (2010) and freshman year (2011). Pet. Exs.
18, 40. Coach Fullerton averred that in the fall of 2010, Petitioner excelled at cross-country, but
in 2011, her pace decreased. Pet. Ex. 40 at ¶¶ 6-7, 10-11. 21 Coach Fullerton also noted that in
the fall of 2011, Petitioner complained of “fatigue, sore legs[,] and lack of energy.” Id. at ¶ 11.

21
A spreadsheet of Petitioner’s cross-country race times with key statistics was filed. See Pet.
Ex. 86. Petitioner’s 2010 average pace was 10:20:50 minutes/mile; her 2011 average pace was
10:59:38 minutes/mile; her pre-vaccine average pace was 10:27:35 minutes/mile; and her post-
vaccine average pace was 11:04:58 minutes/mile. Id. at 1. These numbers differ from those
provided by Coach Fullerton. The times referenced in Coach Fullerton’s affidavit are likely
incorrect. For example, Petitioner likely did not run a 9.01-minute mile for two miles. See Pet.
Ex. 40 at ¶¶ 6-7.

11
VI. EXPERT OPINIONS 22

A. Petitioner’s Expert, Dr. Aaron Lerner 23

1. Background and Qualifications

Dr. Lerner graduated from the Sackler School of Medicine, Tel-Aviv University in Israel
in 1977. Pet. Ex. 87 at 2; Pet. Ex. 88 at 1. In 1984, he completed a pediatric gastroenterology
and nutrition fellowship at Children’s Hospital of Buffalo in New York. Pet. Ex. 87 at 4. He
served as the head of pediatric gastroenterology and nutrition unit at the Carmel Medical Center
in Haifa, Israel from 1988-1995, and again from 2005-2015. Pet. Ex. 88 at 1. Over the course of
his career, he has had “[e]xtensive experience in diagnosis, treatment, follow up, second
opinions[,] and care of thousands of celiac disease patients.” Id. He has also served on various
associations and organizations dealing with celiac disease. Id.

2. Opinion 24

a. Althen Prong One

Dr. Lerner opined that celiac disease is polygenic 25 and that the dominant environmental
factor causally associated with its development is gluten. Pet. Ex. 88 at 14. Gluten “is the
offending inducer[]” of the illness and adherence to a gluten-free diet “is the only effective
therapy.” Id. Although Dr. Lerner acknowledged the role of gluten in causing celiac disease,
here he opined that “the new appearance of [celiac disease] was caused by the Gardasil
vaccination, in a cause and effect relationship.” Id. at 24. He suggested three mechanisms: (1)

22
The record contains expert reports, medical literature, office consult notes, and other evidence
from Dr. Svetlana Blishteyn, M.D. relating to diagnosis and causation of POTS. See Pet. Exs.
28-39, 44-46, 78, 81-82. After those filings, Petitioner narrowed her allegations, and she now
seeks compensation for celiac disease. Joint Submission at 1. Expert reports, medical literature,
and other evidence not offered on the diagnosis or causation of celiac disease have been
reviewed but are not summarized or discussed herein.
23
Dr. Lerner submitted two expert reports. Pet. Exs. 88, 150.
24
Dr. Lerner began his report by a providing a summary of Petitioner’s clinical course. Since a
summary of Petitioner’s medical records is included in this Decision, the undersigned will not
repeat Dr. Lerner’s summary.
25
Polygenic is “pertaining to or determined by the action of multiple different genes.”
Polygenic, Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/dorland/
definition? id=40126 (last visited Feb. 23, 2023).

12
the adjuvant aluminum (“alum”) hydroxyphosphate; (2) an emulsifier, Polysorbate 80; and (3) a
yeast, Saccharomyces cerevisiae (“S. cerevisiae”), 26 used to produce the vaccine. Id. at 23.

According to Dr. Lerner, alum is a “well-defined adjuvant . . . that is able to trigger [an]
immune response.” Pet. Ex. 88 at 23. He viewed alum as “a major environmental factor[]
involved in autoimmunogenesis[] [] in intestinal inflammation and Crohn’s disease induction.”
Id. In support of this opinion, Dr. Lerner cited two articles, which he authored, to explain his
hypothesis of how alum could be “a potential factor” contributing to the induction of or ongoing
inflammation in Crohn’s disease. Pet. Ex. 139 at 1; 27 Pet. Ex. 140 at 1. 28 In both articles, Dr.
Lerner explained that Crohn’s disease is “a chronic relapsing intestinal inflammation in
genetically susceptible individuals and is influenced by yet unidentified environmental factors.”
Pet. Ex. 139 at 1; see also Pet. Ex. 140 at 1.

Alum is a metal widely distributed in the environment and commonly used and primarily
ingested through food, especially food grown in soil rich in the metal. Pet. Ex. 139 at 3. It is
also present in food additives, coffee, cola drinks, spices, tobacco, and cannabis. Id. Regarding
its immune effects, Dr. Lerner suggested that alum compounds “activate antigen-presenting
cells,” enhancing the “uptake of antigens and increase[ing] interleukin (IL)-1 production.” 29 Id.
at 5. The second article referenced by Dr. Lerner also discussed the role of “inflammasome” 30 in
the pathophysiology of Crohn’s disease. Pet. Ex. 140 at 4-5. Neither article discussed celiac
disease.

26
S. cerevisiae is “brewers’ yeast or bakers’ yeast . . . used for alcoholic fermentation and in
leavening bread; it is ubiquitous in the environment and although not considered a human
pathogen, it is increasingly identified in fungal infections, usually in immunocompromised
individuals.” Saccharomyces Cerevisiae, Dorland’s Med. Dictionary Online,
https://www.dorlandsonline.com/dorland/definition?id=104667 (last visited Feb. 23, 2023).
27
Aaron Lerner, Aluminum Is a Potential Environmental Factor for Crohn’s Disease Induction,
1107 Annals N.Y. Acad. Scis. 329 (2007). The complete article was not filed.
28
A. Lerner, Aluminum As an Adjuvant in Crohn’s Disease Induction, 21 Lupus 231 (2012).
The complete article was not filed.
29
Dr. Lerner also stated that injection of alum adjuvants can cause tissue necrosis. Pet. Ex. 139
at 5. However, there is no evidence of tissue necrosis at the site of Petitioner’s HPV
vaccinations. The article also discussed effects of alum hydroxide but that form of alum is not in
the HPV vaccine administered to Petitioner. Pet. Ex. 349 at 12.
30
Inflammasome is “a complex of cryopyrin, caspase-1, and other proteins, found in phagocytic
cells and related to the body's system of innate immunity. Assembly of the inflammasome leads
to activation of caspase-1 and resultant cleavage and activation of interleukins IL-1β and IL18 in
the inflammatory response.” Inflammasome, Dorland’s Med. Dictionary Online,
https://www.dorlandsonline.com/dorland/definition?id=25203 (last visited Feb. 23, 2023).

13
Dr. Lerner’s second proposed mechanism is based on polysorbate 80, used “as a
surfactant, stabilizer[,] and emulsifier . . . in Gardasil.” Pet. Ex. 88 at 23. He asserted that
“[p]olysorbate 80 has been involved in the development of severe non-immunological reactions,
[h]ypersensitivity reaction[,] and . . . autoimmunity induction: colitis, liver dysfunction.” Id. He
referenced three articles for support.

The first is a case report from Badiu et al. 31 of a 17-year-old who development urticaria,
angioedema, conjunctivitis, shortness of breath, and wheezing one hour after she received her
third HPV vaccine. Pet. Ex. 141 at 1. The authors concluded that she had an allergic reaction
due to polysorbate 80 in the vaccine. Id. The relevance of this article is not clear, as the
Petitioner’s medical records do not indicate, and the experts have not opined, that Petitioner had
a hypersensitivity response to the HPV vaccine or any component in the vaccine. Additionally,
the patient in the Badiu et al. case report did not develop celiac disease, or any similar condition
as a result of her HPV vaccination.

Polysorbate 80 is also discussed in an article authored by Chassaing et al. 32 Pet. Ex. 142.
The Chassaing et al. authors conducted a study on mice predisposed to develop changes in the
“microbiota composition and inflammation” and administered emulsifiers
(carboxymethylcellulose or polysorbate 80) in their drinking water for 12 weeks. Id. at 2. The
authors found the mice developed “low-grade inflammation and obesity/metabolic syndrome.”
Id. at 1. Although the complete article was not filed, and specifically the section discussing the
methodology, it appears that the emulsifiers, which were administered orally, altered the
“microbiota composition” in the mice, reducing levels of healthy bacteria and altering “microbial
diversity.” Id. at 2-3. The authors also suggested that emulsifiers promoted colitis in the
susceptible mice, and therefore, they concluded that human consumption of dietary emulsifiers
could affect the microbiota and increase intestinal inflammation. Id. at 3-4. Additional studies
were recommended to determine whether dietary emulsifiers, including polysorbate 80, could
contribute to chronic inflammatory diseases. Id. at 4. Notably, the Chassaing et al. authors
examined the effects of ingesting emulsifiers in drinking water over a period of 12 weeks, not the
effect of one or two doses of 50 mcg of polysorbate 80 injected intramuscularly.

In a “Letter to Editor,” Dr. Lerner and Torsten Matthias 33 suggested that food additives,
including emulsifiers like polysorbate 80, could cause “increased intestinal permeability.” Pet.

31
Iuliana Badiu et al., Hypersensitivity Reaction to Human Papillomavirus Vaccine Due to
Polysorbate 80, 2012 BMJ Case Reps. 1.
32
Benoit Chassaing et al., Dietary Emulsifiers Impact the Mouse Gut Microbiota Promoting
Colitis and Metabolic Syndrome, 519 Nature 92 (2015). Again, the full article was not filed. Dr.
Lerner also provided a second reference on this subject, which appears to be an unpublished
letter to the Editor of Nature, authored by Lerner and Torsten Matthias, commenting on the
article by Chassaing et al. See Pet. Ex. 143. The focus of the letter appears to be food additives
and their effect on intestinal integrity. See id.
33
Aaron Lerner & Torsten Matthias, Multiple Food Additives Enhance Human Chronic
Diseases, 4 SOJ Microbiology & Infectious Disease 1 (2016).

14
Ex. 144 at 1. They recommended further studies to determine whether emulsifiers play a role in
disrupting “intestinal protective mechanisms.” Id. Again, the context was oral ingestion,
specifically the effect of processed foods containing emulsifiers, salt, and other additives. Id.

The third mechanism proposed by Dr. Lerner was based on the yeast, S. cerevisiae, used
to produce the virus-like particles of the HPV vaccine. Pet. Ex. 88 at 23. Dr. Lerner suggested
that the yeast may play a role “since celiac patients mount anti[-S.] cerevisiae antibodies (ASCA)
significantly higher than controls, and the titers are gluten dependent.” 34 Id. at 14. He contended
that ASCA have been described in some autoimmune conditions, including celiac disease. Id.

Dr. Lerner also stated that the virus-like particles contain histones, 35 that potentially
impact “DNA stability, structural integrity[,] and epigenetics.” Pet. Ex. 88 at 23; Pet. Ex. 150 at
9. 36 He did not explain what histones are, how they impact DNA stability, or how this could
cause the HPV vaccine to induce celiac disease.

In support of this theory, Dr. Lerner cited two references about S. cerevisiae. The first is
only an abstract of an article by Toumi et al., 37 which reported on a study that examined the
frequency with which ASCA were found in 238 celiac patients as compared with 80 healthy
controls. Pet. Ex. 145 at 1. The authors noted that ASCA were more prevalent in celiac patients
who were not treated as compared to the control group (27.2% vs. 3.7%) and in adults as
compared to children (35.4% vs. 21.1%). Id. In patients who adhered to a gluten-free diet as
compared to healthy controls, there was no statistical difference in the results. Id. The abstract

34
Dr. Lerner cited an article by Viitasalo et al., reporting the findings of a study showing that
celiac patients may have positive seroreactivity against ASCA and that the titers may decrease
with a gluten-free diet. Pet. Ex. 92 at 1 (Lilsa Viitasalo et al., Early Microbial Markers of Celiac
Disease, 48 J. Clinical Gastroenterology 620 (2014)). The authors did not reach any conclusions
about the significance of their findings.
35
Histones are “any of various simple proteins containing many basic groups, soluble in water
and insoluble in dilute ammonia; the globin of hemoglobin is a histone. Combined with nucleic
acids they form nucleohistone and are associated with DNA in chromatin. Some are poisonous
and contain a great deal of phosphorus. Blood treated with histone is altered and has lower
coagulability.” Histone, Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/
dorland/definition?id=22791 (last visited Feb. 23, 2023).
36
An article filed by Dr. Lerner discussed the issue of low structural stability in virus-like
particles that are produced in S. cerevisiae, but the concern was about “reduced antigenicity and
immunogenicity” and not induction of any autoimmune illness. Pet. Ex. 93 (Hyoung Jin Kim et
al., The Concentration of Carbon Source in the Medium Affects the Quality of Virus-Like
Particles of Human Papillomavirus Type 16 Produced in Saccharomyces Cerevisiae, 9 Plos One
e94467 (2014)).
37
D. Toumi et al., Anti-Saccharomyces Cerevisiae Antibodies in Coeliac Disease, 32
Scandinavian J. Gasteroenterology 821 (2007).

15
does not mention the HPV vaccine or suggest that S. cerevisiae plays a role in the etiology of
celiac disease.

The second article, by Kim et al., 38 is highly technical, and Dr. Lerner did not explain it,
or its relevance to his theory. See Pet. Ex. 146. The article described histones found in
pseudoviruses (synthetic viruses) used to provide systems “for evaluating anti-viral agents and
vaccine candidates.” Id. at 1. Synthetic viruses are similar in their “structures and
characteristics” to native viruses but fundamentally differ because they lack the ability to
replicate. Id. Native HPV is technically difficult to produce. Id. at 2. Based on their research,
the authors concluded that “the involvement of large amounts of cellular histones during
[pseudovirus] formation interferes with the structural integrity of the [pseudoviruses] and affects
their immunogenicity.” Id. at 1. They also determined the amount of histones “most suitable”
for use in an HPV pseudovirus.” Id. The authors did not discuss adverse effects of the HPV
vaccine, or celiac disease, or state that histones in the HPV vaccine cause any adverse effects, or
otherwise relate to the issues here.

As an aside, Dr. Lerner stated that “even the intraepithelial lymphocytes that invade the
HPV neoplastic lesions are gut derived, thus strengthening the gut-reproductive system cross-
talks in the gut-vi[r]ginal axis.” Pet. Ex. 88 at 23. Dr. Lerner did not explain this sentence or
how it related to this theory. He cited to an abstract of an article authored by Kojima et al., 39
which described a study that classified the type of lymphocytes found in cervical intraepithelial
neoplastic lesions (presumably caused by HPV wild infection). 40 Pet. Ex. 147 at 1. The
relevance of the abstract is not clear.

In addition to proposing the three mechanisms described above, Dr. Lerner opined that
the HPV vaccine is associated with an increased incidence of autoimmune illnesses, including
Bechet’s syndrome, Raynaud’s disease, diabetes, Hashimoto’s thyroiditis, central nervous
system conditions, alopecia, vasculitis, and systemic lupus erythematosus. Pet. Ex. 88 at 22; see
also Pet. Ex. 150 at 6-7 (citing Pet. Exs. 190-91, 193-94). He also asserted that ulcerative colitis
and Crohn’s disease are new-onset illnesses that occur after HPV vaccination. Pet. Ex. 88 at 22;
Pet. Ex. 150 at 7. The references cited by Dr. Lerner in support of these statements, however, do

38
Hyoung Jin Kim et al., Characterization of Human Papillomavirus Type 16 Pseudovirus
Containing Histones, 16 BMC Biotechnology 1 (2016). Only the first five pages of this 10-page
article were filed.
39
S. Kojima et al., Characterization of Gut-Derived Intraepithelial Lymphocyte (IEL) Residing
in Human Papillomavirus (HPV)-Infected Intraepithelial Neoplastic Lesions, 66 Am. J.
Reproductive Immunology 435 (2011).
40
The Gardasil vaccine is prescribed for the prevention of “[c]ervical intraepithelial neoplasia.”
Pet. Ex. 349 at 1-2.

16
not mention celiac disease associated with HPV vaccination. See Pet. Ex. 133; 41 Pet. Ex. 134 at
1. 42 The second reference identified celiac disease as a “new-onset” autoimmune illness. Pet.
Ex. 134 at 1.

Next, Dr. Lerner cited several articles that reported the incidence of adverse events
following HPV vaccination, and he asserted they showed that celiac disease was associated with
the HPV vaccination. 43 Pet. Ex. 88 at 22. One of these is authored by Cameron et al. 44 and
reported on a Scottish study using hospital chart data from 2004 to 2014. Pet. Ex. 136 at 1.
“[W]hile small increases in incidence were observed for Bell’s palsy, [celiac] disease, ovarian
dysfunction, . . . diabetes, demyelinating disease[,] and juvenile rheumatoid arthritis, none [were]
statistically significant.” Id. The authors acknowledged that hospital data “only capture[s]
severe cases, which may under-estimate the incidence of diseases that can present with variable
severity.” Id. at 5. Dr. Lerner agreed and opined that many studies “were done on medical
records, on hospitalized or outpatient clinics, and since [celiac disease] is mildly or hypo
symptomatic clinically,” patients seldom require hospitalization. Pet. Ex. 150 at 9. Thus, he
believed the incidence of the disease after vaccination as reflected in these studies is
underestimated. Id. at 8-9.

Dr. Lerner also referenced a Brazilian paper by Nicol et al., 45 which reviewed peer-
reviewed literature about reported adverse effects following HPV vaccinations. Pet. Ex. 137 at
1. The most common adverse effects were “pain and swelling at the injection site followed by
fatigue, fever, gastrointestinal symptoms[,] and headaches.” Id. at 2.

Lastly, Dr. Lerner opined that there is a “major conflict of interest” problem 46 with many
HPV vaccine safety studies performed by vaccine manufactures, which he believed affects the
“validity of the results and conclusions.” Pet. Ex. 150 at 8. He cited the “classic example:”

41
David A. Geier & Mark R. Geier, A Case-Control Study of Quadrivalent Human
Papillomavirus Vaccine-Associated Autoimmune Adverse Events, 34 Clinical Rheumatology
1225 (2015).
42
Matti Lehtinen et al., Safety of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted
Vaccine in Adolescents Aged 12-15 Years: Interim Analysis of a Large Community-
Randomized Controlled Trial, 12 Hum. Vaccines & Immunotherapies 3177 (2016). This is only
an abstract. The full article was filed by Respondent. See Resp. Ex. T, Tab 13.
43
One of the references was an abstract. See Pet. Ex. 134.
44
R. L. Cameron et al., Adverse Event Monitoring of the Human Papillomavirus Vaccines in
Scotland, 46 Internal Med. J. 452 (2016).
45
A.F. Nicol et al., HPV Vaccines: A Controversial Issue?, 49 Brazilian J. Med. & Biological
Rsch. 1 (2016).
46
See Pet. Ex. 137 at 1 (recommending “a more independent monitoring system” to assess for
adverse effects in order to address the conflict of issue concerns raised by Dr. Lerner).

17
Chao et al. 47 Id. (citing Pet. Ex. 199). Chao et al., a study supported by vaccine manufacturers
like Merck, reviewed the medical records of two Kaiser facilities from 2006 and 2010 to assess
the safety of the HPV4 vaccine, particularly regarding autoimmune illnesses. Pet. Ex. 199 at 1-2.
Chao et al. reported that there was “no cluster of disease onset in relation to vaccination timing,
dose sequence[,] or age . . . for any autoimmune condition.” 48 Id. at 1.

b. Althen Prong Two

Regarding a logical sequence of cause and effect, Dr. Lerner opined that Petitioner’s
celiac disease is “directly connected” to the HPV vaccine. Pet. Ex. 150 at 9. He opined that the
Petitioner had “definitive” celiac disease, and had “no manifestations” of the illness prior to
August 30, 2011, when she received her first HPV vaccination. Id.

Dr. Lerner noted that Petitioner’s family members have autoimmune illnesses, and that
Petitioner had “the predisposing genetics” for celiac disease, primarily HLA-DQ2/8, 49 which is
“positive in 95%” of patients with celiac disease. Pet. Ex. 88 at 21-22.

Further, Dr. Lerner explained that “[celiac disease] can present acutely and multiple acute
presentations are described in the literature.” Pet. Ex. 150 at 9. Celiac disease can also present
with “acute, severe anemia.” Id. In celiac disease, iron deficiency anemia is caused by
“malabsorption due to intestinal atrophic damage, [b]lood loss[] in the stool, inadequate iron
intake[,] and the anemia of chronic disease with enterocyte sequestration of iron.” Pet. Ex. 88 at
17. Dr. Lerner opined that Petitioner had iron deficiency anemia commonly seen in celiac
disease. Id. at 16-17.

c. Althen Prong Three

Dr. Lerner did not provide an opinion about what the expected temporal relationship
would be between vaccination and disease onset for his three proposed mechanisms. For
example, he did not state how long it would take for the adjuvant alum to trigger an immune
response that would manifest as celiac disease.

47
C. Chao et al., Surveillance of Autoimmune Conditions Following Routine Use of
Quadrivalent Human Papillomavirus Vaccine, 271 J. Internal Med. 193 (2012).
48
For references critical of Chao et al., see Pet. Ex. 179 (L. Tomljenovic & C. A. Shaw, No
Autoimmune Safety Signal After Vaccination with Quadrivalent HPV Vaccine Gardasil?, 272 J.
Internal Med. 514 (2012)); Pet. Ex. 180 (L. Tomljenovic & C. A. Shaw, Human Papillomavirus
(HPV) Vaccine Policy and Evidence-Based Medicine: Are They at Odds?, 45 Annals Med. 182
(2013)); Pet. Ex. 190 (Y. Shoenfeld, HPV Vaccines and Autoimmune Diseases, 272 J. Internal
Med. 98 (2012)).
49
The results of testing for these genes were not included in Petitioner’s medical records, and it
is not clear that Petitioner was ever tested for them. It appears that Dr. Lerner is suggesting that
that Petitioner may have these genes by virtue of her diagnosis and family history, which is
positive for autoimmune illnesses.

18
He did opine as to onset of Petitioner’s celiac disease. According to Dr. Lerner,
Petitioner’s complaints began in the “weeks to months” after her first HPV vaccine and her “full
clinical presentation,” based on Dr. Kunde’s records, was “apparent during Nov[ember] 2011.”
Pet. Ex. 150 at 9. More specifically, Dr. Lerner opined that Petitioner’s onset was approximately
November 10, 2011. Pet. Ex. 88 at 17. He based this opinion on the following medical record
and affidavit evidence.

Petitioner first saw Dr. Kunde on January 10, 2012 and reported that her “tiredness”
began in the summer of 2011. Pet. Ex. 88 at 17. In the prior two months, she had weight loss,
abdominal pain, anemia, and aching bones. Id. “Extrapolating and approximating those data,”
Dr. Lerner opined that Petitioner’s celiac disease “started to manifest around [November 10,]
2011, in between the [two] HPV vaccinations.” Id. Dr. Lerner also noted that on January 11,
2012, Petitioner reported loose stools and shortness of breath that had worsened over the last
week. Id.

Additionally, Dr. Lerner explained that the multiple affidavits from Petitioner, her family,
and her coaches described Petitioner as extremely active and healthy prior to August 30, 2011,
and that her first symptoms of illness began “weeks [to a] few months” after her first HPV
vaccination. Pet. Ex. 88 at 17.

There is considerable evidence in the record about Petitioner’s cross-country times and
physical performance during sports both before and after vaccination. Dr. Lerner devoted
several pages of his first expert report discussing his opinions about this information. See Pet.
Ex. 88 at 18-21. He explained that there are “complicated, multi-fact[ed,] and interrelated
aspects that influence physical performance, in general and in [celiac disease].” Id. at 18. These
factors include pre-exercise nutrition, course parameters and conditions, the environment and
weather, hormones and menstruation, psychological factors, and anemia. Id. at 18-19. Since
information about all these factors is not available, Dr. Lerner did not believe that it was
appropriate to compare Petitioner’s race results before and after vaccination in order to draw
conclusions as to onset of her celiac disease. Id. at 19-21.

Further, Dr. Lerner did not believe that Respondent’s expert could conclude that
Petitioner had anemia prior to her vaccination on August 30, 2011. Pet. Ex. 150 at 5. The initial
labs that established Petitioner was anemic were not done until January 5, 2012. Id. Dr. Lerner
also opined that “iron deficiency anemia can present acutely.” Id. If Petitioner had anemia
earlier than August 30, 2011, Dr. Lerner argued that she would have had “more severe
symptomatology, clinical signs[,] and morbidity.” Id. He cited an abstract of an article by
Saukkonen et al., 50 which stated that “[c]eliac patients with anemia had more severe disease than
nonanemic patients in terms of the serology and a lower BMI.” Pet. Ex. 104 at 1. While the
abstract reported that 23% of patients (out of 163 adults) in the study had anemia when
diagnosed, and this group had more gastrointestinal symptoms, higher antibody values, and

50
J. Saukkohen et al., Clinical Characteristics and the Dietary Response in Celiac Disease
Patients Presenting With or Without Anemia, 51 J. Clinical Gastroenterology 412 (2017).

19
lower iron values, the abstract did not speak to the question of how long it took for patients to
develop the symptoms described, or whether their presentations were acute or chronic. 51 See id.

In summary, Dr. Lerner opined that Petitioner’s manifestation of celiac disease was
weeks to a few months after her first HPV vaccination, and specifically that her approximate
onset was November 10, 2011. Pet. Ex. 88 at 17.

B. Petitioner’s Expert, Dr. Yehuda Shoenfeld 52

1. Background and Qualifications

Dr. Shoenfeld’s “clinical scientific works focus on autoimmune/rheumatic diseases.”
Pet. Ex. 320 at 1. After graduating from medical school, he completed fellowships in
hematology and oncology and a master in internal medicine from Tel-Aviv University. Pet. Ex.
205 at 3. He founded and served as Director of the Center for Autoimmune Diseases at the
Sheba Medical Center in Israel. Id.; Pet. Ex. 320 at 1. He has published more than 2,000 peer
reviewed papers, 28 books, and 300 chapters in medical books on vaccinations and
autoimmunity. Pet. Ex. 320 at 1-2.

2. Opinion

a. Althen Prong One

Dr. Shoenfeld explained that one’s response to vaccination, intended to provide
protective immunity, is like a response to infection. Pet. Ex. 320 at 9. Dr. Shoenfeld opined that
vaccinations, like infections, can induce autoimmunity. Id. There are several mechanisms by
which infections can cause autoimmunity, and the most common of these is “molecular mimicry
between infectious antigens and self-antigens.” 53 Id. (emphasis omitted). Moving to vaccines,
and specifically, the HPV vaccine, Dr. Shoenfeld opined that “it is [] possible that molecular
mimicry plays a role in mediating autoimmunity following HPV vaccination.” Id. at 11.

51
In another abstract filed by Dr. Lerner, the authors compared celiac patients who presented
with anemia compared to those who had diarrhea on presentation. Pet. Ex. 110 at 1 (H. Abu
Daya et al., Celiac Disease Patients Presenting with Anemia Have More Severe Disease Than
Those Presenting with Diarrhea, 11 J. Clinical Gastroenterology & Hepatology 1472 (2013)).
They found “[a]nemic patients were more than [two]-fold more likely to have severe villous
atrophy and a low bone mass density at the time” of diagnosis. Id.
52
Dr. Shoenfeld filed several expert reports. Pet. Exs. 320-21, 325, 337. Some of these expert
reports discuss myasthenia gravis, POTS, CFS, and small fiber neuropathy. Petitioner is no
longer seeking compensation for these alleged vaccine-related illnesses. See Joint Submission at
1. Since Petitioner now alleges that her vaccine injury is celiac disease, the portions of Dr.
Shoenfeld’s reports that examine other illnesses are not discussed by the undersigned.
53
The other mechanisms Dr. Shoenfeld listed are epitope spreading, polyclonal activation of B
lymphocytes, and bystander activation. Pet. Ex. 320 at 9.

20
Relative to molecular mimicry and the HPV vaccine, Dr. Shoenfeld suggested several
avenues for cross-reactivity. The first one is taken from an article by Kanduc, 54 who
investigated amino acid sequence similarity between HPV16 and human proteins to quantify the
possible cross-reactivity risk of an HPV16 vaccine. 55 Pet. Ex. 344 at 1. Kanduc identified
amino acid sequences 56 which “might lead to pathologies including spinal muscular atrophy,
proximal muscle weakness . . . , cardiovascular and musculoskeletal abnormalities, disorders of
lipoprotein metabolism . . . , and increased [susceptibility] to coronary artery disease.” Id. at 2,
2-10 tbl.1. Kanduc, however, did not identify celiac disease as one of the illnesses that might be
caused by cross-reactivity due to HPV16.

Next, Dr. Shoenfeld suggested that the HPV16 L1 protein antigen 57 in the vaccine shares
a pentapeptide (KPPIG) 58 with the human protein “Signal Transducer and Activator of
Transcription 3 ([] STAT3).” Pet. Ex. 321 at 3. He described STAT3 as a “protein that mediates
cellular responses to interleukins,[59] binds to interleukin-6 (IL-6)-responsive elements identified
in the promoters of various acute-phase protein genes, [] [and] [a]cts as a regulator of

54
Darja Kanduc, Quantifying the Possible Cross-Reactivity Risk of an HPV16 Vaccine, 8 J.
Experimental Therapeutics & Oncology 65 (2009).
55
The Petitioner received the Gardasil HPV vaccine which includes the HPV16 viral strain. See
Pet. Ex. 349.
56
The word “sequence” is used here to simplify the discussion. Kanduc’s searches involved
heptamer amino acid sequences, or sequences consisting of seven. Pet. Ex. 344 at 1.
57
The Gardasil vaccine “is a non-infectious recombinant quadrivalent vaccine prepared from the
purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and
18. The L1 proteins are produced by separate fermentations in recombinant [S.] cerevisiae and
self-assembled into VLPs. The fermentation process involves growth of S. cerevisiae on
chemically-defined fermentation media which include vitamins, amino acids, mineral salts, and
carbohydrates.” Pet. Ex. 349 at 12.
58
As support for this opinion, Dr. Shoenfeld stated that the KPPIG protein structure “is part of
four epitopes that have been cataloged as immunopositive in humans at the Immune Epitope
Database.” Pet. Ex. 321 at 4, 5 tbl.1. It does not appear evidence from this database has been
filed.
59
An interleukin is “a generic term for a group of multifunctional cytokines that are produced by
a variety of lymphoid and nonlymphoid cells and have effects at least partly within the
lymphopoietic system; originally believed to be produced chiefly by and to act chiefly upon
leukocytes.” Interleukin, Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/
dorland/definition?id=25582 (last visited Feb. 23, 2023).

21
inflammatory response by regulating differentiation of naïve CD4+ T-cells[60] into T-helper Th17
or regulatory T-cells (Treg).” Id.

Relative to Dr. Lerner’s opinion that S. cerevisiae may be associated with autoimmunity,
Dr. Shoenfeld opined that the “pentapeptide KPPIG is [] present in two proteins of [S.]
cerevisiae,” and he suggested this may be “a possible contribution” to autoimmunity. Pet. Ex.
321 at 4 (emphasis added). Dr. Shoenfeld explained that “the autoimmunity against STAT3
triggered by HPV16 L1 might be potentiated by autoimmunity triggered by [S.] cerevisiae.” Id.
(emphasis added). Additionally, “[a]lterations of STAT3 are associated with childhood onset of
a spectrum of autoimmune manifestations . . . including autoimmune enteropathy[61] or celiac
disease.” Id.

In support of his opinion that STAT3 plays a role in the development of autoimmune
disease, Dr. Shoenfeld cited three articles that establish that autoimmune illnesses are found in
patients with STAT3 mutations; however, they did not report that vaccinations in general, or the
HPV vaccine specifically, play any role in inducing illness in those who have these mutations.
Flanagan et al. 62 reported STAT3 de novo mutations 63 in five children with polyautoimmune
diseases (diabetes, enteropathy, interstitial lung disease, juvenile-onset arthritis, hypothyroidism,
short stature, and eczema). Pet. Ex. 345 at 1-3. Four of the five children had diabetes, short
stature, and eczema. Id. at 3. The authors noted that “[t]he young age at diagnosis [0-43 weeks
of age] . . . [was] consistent with STAT3 mutations causing accelerated autoimmune disease.”
Id. (emphasis omitted). Celiac disease was not identified as one of the illnesses associated with
STAT3 mutations. See id. at 10 fig.2.

60
CD4 cells are “T lymphocytes that carry the CD4 antigen; they are helper T cells.” CD4 Cells,
Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=
63999 (last visited Feb. 23, 2023). Helper cells are “differentiated T lymphocytes whose
cooperation (help) is required for the production of antibody against most (T-dependent)
antigens.” Helper Cells, Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/
dorland/definition?id=64157 (last visited Feb. 23, 2023).
61
Enteropathy is “any disease of the intestines.” Enteropathy, Dorland’s Med. Dictionary
Online, https://www.dorlandsonline.com/dorland/definition?id=16610 (last visited Feb. 23,
2023).
62
Sarah E. Flanagan et al., Activating Germline Mutations in STAT3 Cause Early-Onset Multi-
Organ Autoimmune Disease, 46 Nature Genetics 812 (2014).
63
A de novo mutation is “a change in the DNA sequence of a gene that is seen for the first time
in a person and has not appeared in previous generations. A de novo mutation can explain how a
person can have a genetic condition that did not occur in his or her parents.” De Novo Mutation,
Nat’l Cancer Inst., https://www.cancer.gov/publications/dictionaries/cancer-terms/def/de-novo-
mutation (last visited Feb. 23, 2023).

22
Haapaniemi et al. 64 explored the role of STAT3 mutations in primary immunodeficiency
syndromes. Pet. Ex. 346 at 1. By way of background, the authors explained that STATs
function as “transcription factors [that] orchestrate hematopoietic [blood] cell differentiation.”
Id. Mutations in “STAT3 have been linked to development of immunodysregulation
polyendocrinopathy enteropathy X-linked-like syndrome,” “hyperimmunoglobulin E (IgE)
syndrome,” and “large granular lymphocytic (LGL) leukemia.” Id. at 1-2 (emphasis omitted).
The paper presented an evaluation of three patients who had de novo STAT3 mutations. Id. at 2.
Two of the patients had “aggressive multiorgan autoimmunity and lymphoproliferation,
including pediatric LGL leukemia.” Id. The third patient “developed disseminated
mycobacterial disease in late adolescence.” Id. There is no indication that any of the children
had adverse reactions to vaccinations, and it is specifically noted that patient number three had
normal reactions to her vaccinations (it is not known, however, whether this included the HPV
vaccination). 65 Id.

The third article, by Milner et al., 66 described autoimmune illnesses associated with nine
different STAT3 mutations. Pet. Ex. 347 at 1. The patients “exhibited a variety of clinical
features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity
(lung, gastrointestinal, hepatic, and/or endocrine dysfunction), infections, and short stature.” Id.
The most prominent presentation was “hemolytic anemia, neutropenia, and/or
thrombocytopenia.” Id. at 3. Celiac disease was not referenced, and vaccination, specifically
HPV vaccination, was not described as playing any role in the induction of illnesses associated
with the STAT3 mutations.

In addition to implicating molecular mimicry as a mechanism, Dr. Shoenfeld also
suggested that adjuvants in vaccines may play a causative role since they “induce a more
vigorous immune response to the vaccinated antigens.” Pet. Ex. 320 at 9-10. “The HPV vaccine
uses [alum] salt as an adjuvant . . . .” Id. at 10. Dr. Shoenfeld asserted that adjuvants, which are
expected to stimulate the immune system, have been “found to induce” illness. Id. He
referenced “adjuvant disease” 67 and cited an article he co-authored on ASIA, an autoimmune

64
Emma M. Haapaniemi et al., Autoimmunity, Hypogammaglobulinemia, Lymphoproliferation,
and Mycobacterial Disease in Patients with Activating Mutations in STAT3, 125 Blood 639
(2015).
65
Patient two was noted to have celiac disease. Pet. Ex. 346 at 2, 3 tbl.1. The authors did not
suggest or opine that vaccinations caused or contributed to the patient’s celiac disease.
66
Joshua D. Milner et al., Early-Onset Lymphoproliferation and Autoimmunity Caused by
Germline STAT3 Gain-of-Function Mutations, 125 Blood 591 (2015).
67
Dr. Shoenfeld discussed concerns related to “macrophagic myofasciitis (MMF) lesion[s]
detected in patients with myalgic encephalomyelitis/[CFS].” Pet. Ex. 321 at 5. There is no
evidence, however, to suggest that Petitioner had MMF or any such lesion.

23
syndrome which he postulated may be caused by adjuvants. Id. (citing Pet. Ex. 254). 68 In the
paper, he “suggest[ed] the possibility of accelerated autoimmunity/inflammation following
vaccination” due to adjuvants. Id. at 3. The paper did not identify celiac disease as one caused
by adjuvants.

Regarding the effect of adjuvants, Dr. Shoenfeld stated that “vaccines are designed to
hyper-stimulate antibody production . . . which is accomplished via the immuno-stimulatory
properties of adjuvants.” Pet. Ex. 320 at 11. He opined that adjuvants “augment the molecular
mimicry of the viral particles” of the vaccine. Id. at 12. He cited an article from Watad et al., 69
which he was a named author, that explained that adjuvants are used “to induce a more potent
response to a microbial antigen” that would “produce a higher titer of antibodies, which would
eventually confer better protection.” 70 Pet. Ex. 341 at 1. 71 However, the paper did not suggest
that adjuvants increase the likelihood of autoimmune reactions to vaccines, or play a role in the
mechanism of molecular mimicry to induce an autoimmune illness.

Again, discussing hyperstimulation of the immune system, Dr. Shoenfeld suggested that
“due to the high antigenicity of the [HPV vaccine],” as compared to natural HPV infection, and
the “immuno-stimulatory properties of adjuvants,” the HPV vaccine “may be more likely to
trigger autoimmune adverse manifestation[s]” as compared to a natural infection. Pet. Ex. 320 at
11-12. He did not explain, however, how adjuvants could trigger autoimmune illness.

Another concept discussed by Dr. Shoenfeld relates to “polyautoimmunity,” or “the
presence of more than one autoimmune disease[].” Pet. Ex. 320 at 7; see also Pet. Ex. 337 at 1-
2. He explained that patients who are “genetically prone to develop autoimmune disease are
more prone to develop a second autoimmune disease.” Pet. Ex. 337 at 1. He opined that “[i]f
the environmental factor claimed to induce the autoimmune disease exists and was not
discontinued to affect the body, there is a great possibility that it will induce . . . a second
autoimmune disease.” Id. Risk factors for polyautoimmunity include family history, female

68
Yehuda Shoenfeld & Nancy Agmon-Levin, ‘Asia’—Autoimmune/Inflammatory Syndrome
Induced by Adjuvants, 26 J. Autoimmunity 4 (2011).
69
Abdulla Watad et al., Immunologist’s Little Dirty Secret Finger: A Case Report of
Polyautoimmunity Following an Accidental Self-Injection of Complete Freund’s Adjuvant, 22
Isr. Med. Ass’n J. 393 (2020).
70
See also Pet. Ex. 188 (A. Watad et al., Autoimmune/Inflammatory Syndrome Induced by
Adjuvants (Shoenfeld’s Syndrome)—An Update, 0 Lupus 1 (2017)).
71
The article described a case report after a scientist was accidentality injected with complete
Freund’s adjuvant. Pet. Ex. 341 at 1. This adjuvant is not used in the HPV vaccine but has been
used to induce experimental animal models of autoimmune disease, including experimental
autoimmune encephalomyelitis. Id. at 1-2. Complete Freund’s adjuvant “elicits cell-mediated
immunity (delayed hypersensitivity), as well as humoral antibody formation.” Freund Adjuvant,
Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/dorland/definition?
id=55029 (last visited Feb. 23, 2023).

24
gender, the presence of certain autoantibodies (including anti-gliadin immunoglobulin G (“IgG”)
antibodies in celiac disease), and vitamin D deficiency. Pet. Ex. 320 at 7-9.

In the context of polyautoimmunity, Dr. Shoenfeld opined that “it is more probabl[e] than
not that the vaccine resulted in a pro[-]inflammatory state that contributed [to] the development
of this phenomenon in the genetically susceptible [P]etitioner with a rich genetic background.” 72
Pet. Ex. 321 at 10. He did not, however, explain how the HPV vaccine could cause a pro-
inflammatory state or otherwise contribute to the development of celiac disease.

b. Althen Prong Two

Dr. Shoenfeld opined that Petitioner was healthy prior to vaccination, and after her HPV
vaccination, she developed celiac disease. Pet. Ex. 321 at 11. He asserted that because “[t]he
symptoms began following the Gardasil vaccinations, . . . the vaccine was the most probable
triggering factor.” Pet. Ex. 320 at 7. Similarly, he stated “in the absence of any other
confounders, the time relationship, the plausible mechanism, the logical sequence, positive
antibody studies, and the previously reported cases support the notion that it is more reasonable
than not that the diagnosis of . . . celiac disease occurred after Gardasil administration.” Pet. Ex.
321 at 11; see also Pet. Ex. 320 at 19.

Moreover, he opined that the “autoantibodies generated in response to Gardasil
vaccination caused or contributed to the development of [Petitioner’s] many autoimmune
diseases.” Pet. Ex. 325 at 1. He contended that “anti-β adrenergic receptor autoantibodies[73]
specifically can be generated in response to Gardasil and those antibodies have been implicated
in the development of some of [Petitioner’s] conditions.” Id. In Petitioner’s case, he opined that
these included ANA and anti-tTG antibodies. Id. Dr. Shoenfeld failed to provide any

72
Dr. Shoenfeld cited three articles to support this statement, but the articles were not filed. See
Pet. Ex. 321 at 10 (noting references 20-22 for support).
73
An adrenergic receptor is “a site on an effector organ innervated by postganglionic adrenergic
fibers of the sympathetic nervous system, classified as either α-adrenergic or β-adrenergic
according to its reaction to norepinephrine and epinephrine, as well as to certain blocking and
stimulating agents.” Adrenergic Receptor, Dorland’s Med. Dictionary Online,
https://www.dorlandsonline.com/dorland/definition?id=102533 (last visited Feb. 23, 2023). β
adrenergic receptors “are subdivided into two basic types: β1, found in the myocardium and
causing lipolysis and cardiac stimulation, and β2, found in smooth and skeletal muscle and liver
and causing bronchodilation, vasodilation, and increased presynaptic release of norepinephrine.
A third type, β3, is atypical; it is more sensitive to norepinephrine than to epinephrine, is
relatively resistant to propranolol blockade, and may be involved in lipolysis regulation in
adipose tissue.” β-Adrenergic Receptors, Dorland’s Med. Dictionary Online,
https://www.dorlandsonline.com/dorland/definition?id=102536 (last visited Feb. 23, 2023).

25
foundational support for his opinion that the HPV vaccine can cause or did cause Petitioner to
develop positive tTG or ANA antibodies. 74

Regarding the application of polyautoimmunity here, Dr. Shoenfeld opined that “[b]ased
on [Petitioner’s] genetic history, her female gender, and the presence of numerous autoimmune
diseases, . . . she was predisposed to autoimmune diseases prior to the HPV vaccinations, and
after the HPV vaccinations transposed her first autoimmune disease, the additional diseases
followed as a result.” Pet. Ex. 320 at 9. Without evidentiary support, this notion of
“transposition” is without foundation and conclusory.

Additionally, Dr. Shoenfeld opined that Petitioner’s active participation in sports caused
“an enhanced reaction to vaccine.” Pet. Ex. 320 at 16. He continued, “[t]hey are like women
and those who carry a genetic marker i.e., HLA DRB1. Therefore, [Petitioner] being a young
woman active in sport subjected to the vaccine which contain molecular mimicry motifs together
with adjuvants, gaining a genetic preponderance—developed the autoimmune reaction.” Id. at
16-17 (internal citations omitted).

In support of his opinion that Petitioner’s participation in sports enhanced her reaction to
the vaccine, Dr. Shoenfeld cited two articles. The first, by Pascoe et al., 75 is a literature review
of published studies that examined the effects of exercise on vaccination. Pet. Ex. 267 at 1. The
authors explained that “[e]xercise has been identified as a [] factor that can boost immune
function in some settings and therefore potentially serve as an adjuvant for immune responses.”
Id. at 2. The findings suggested a “positive association between exercise and the immune
response to vaccination, particularly in populations at risk for immune dysfunction, such as older
adults” who have “sub-optimal responses to vaccination” due to aging. Id. at 7-8. Data in
“young adult cohorts” was limited, with “only one study showing limited evidence for greater
responses in participants with higher levels of physical activity.” Id. at 7. The HPV vaccine was
not studied.

The second article, authored by Woods et al., 76 presented the findings of a study
addressing whether moderate cardiovascular exercise or flexibility and balance training affected
antibody responses to the influenza vaccination in sedentary older adults. Pet. Ex. 268 at 1. The
study showed that “10 months of cardiovascular exercise training extended the antibody response
afforded by influenza vaccination.” Id. at 7. The HPV vaccine and younger adults were not
studied, and so it is not clear whether the results would be relevant here. Assuming the results
are applicable, the presumption is that exercise enhances the antibody response to vaccination.

74
Dr. Shoenfeld asserted that these specific antibodies are associated with “induction of several
overlapping conditions, which include POTS and CFS.” Pet. Ex. 325 at 2.
75
April R. Pascoe et al., The Effects of Exercise on Vaccination Responses: A Review of
Chronic and Acute Exercise Interventions in Humans, 39 Brain Behavior & Immunity 33 (2014).
76
Jeffrey A. Woods et al., Cardiovascular Exercise Training Extends Influenza Vaccine
Seroprotection in Sedentary Older Adults: The Immune Function Intervention Trial, 57 J. Am.
Geriatrics Soc’y 2183 (2009).

26
This is a desired outcome, not an adverse outcome. The articles did not suggest that exercise
increases the risk of developing autoimmune illnesses post-vaccination.

c. Althen Prong Three

Dr. Shoenfeld opined that “[P]etitioner clearly developed celiac disease after receiving
the first vaccination with HPV.” Pet. Ex. 321 at 2. He stated that she “developed symptoms
within weeks of receiving the Gardasil vaccination, and most notably after the second dose of the
vaccination.” Pet. Ex. 320 at 19. While initially opining that Petitioner developed symptoms
“within weeks” of vaccination, in a subsequent expert report, Dr. Shoenfeld opined that she
developed symptoms “within [two] months of Gardasil administration.” Id.; Pet. Ex. 321 at 11.

According to Dr. Shoenfeld, the “nature of autoimmune disease[s] and their development
follow a more gradual course.” Pet. Ex. 321 at 10. He cited a study by Ozawa et al., 77 that
discussed the time frame between HPV vaccination and the onset of adverse reactions. Id. Dr.
Shoenfeld stated that Ozawa et al. “noted that it is rather difficult to determine the exact time of
onset [of] these symptoms.” Id. “Thus, the interval from an initial injection of HPV vaccine
until the first awareness of these symptoms may vary among the involved patients. Taken
together, while it takes some time for the diseases to fully manifest, post[-]vaccination symptoms
could start with [a] quite long latency period post[-]vaccination.” Id. at 11.

C. Respondent’s Expert, Dr. Chris A. Liacouras

1. Background and Qualifications

Dr. Liacouras is a board-certified pediatric gastroenterologist with approximately 30
years of clinical practice. Resp. Ex. T at 1, 3. He is a Professor of Pediatrics at the Perelman
School of Medicine at the University of Pennsylvania and at the Children’s Hospital of
Philadelphia in the Division of Gastroenterology, Hepatology, and Nutrition. Id. at 3; Resp. Ex.
U at 2. Dr. Liacouras has also worked as the Medical Director of the Children’s Hospital of
Philadelphia’s Center for Gastrointestinal Endoscopy, the Chairman of Pediatric Endoscopy for
the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, and the
Chairman for Pediatric Endoscopy of the American Society of Gastrointestinal Endoscopy.
Resp. Ex. T at 3; Resp. Ex. U at 2-3. Over the course of his career, he has “extensively
published in the field of pediatric gastroenterology;” has “evaluated between 2000-3000
pediatric patients, who have had all types of disorders of the gastrointestinal system, every year
since 1991;” and has “evaluated or consulted on more than 500 pediatric patients who have had
celiac disease.” Resp. Ex. T at 3; see also Resp. Ex. U at 9-21.

77
This study was not cited by Dr. Shoenfeld in his list of references at the end of his expert
report, nor was it filed. See Pet. Ex. 321 at 12-13; Pet. Ex. List, filed Oct. 21, 2021 (ECF No.
279).

27
2. Opinion

Dr. Liacouras cited medical literature explaining that “[c]eliac disease [] is an immune-
mediated systemic disorder elicited by the ingestion of wheat gliadin[78] and related prolamins[79]
in genetically susceptible individuals.” 80 Resp. Ex. T, Tab 19 at 1. 81 In a person with celiac
disease, tTG antibodies “damage the small intestinal mucosa, which may cause villous atrophy.”
Resp. Ex. T, Tab 14 at 1. 82

According to Dr. Liacouras, the presentation of celiac disease in adolescents and adults is
“more insidious” than in young children. Resp. Ex. T at 5. He opined that symptoms in
adolescent athletes may be present for months or years before diagnosis, due to the varied
symptoms which may be vague or atypical, such as fatigue and muscle and joint pain. Id. These
symptoms may occur well before a diagnosis is made. Id. Fatigue is “caused by chronic
malabsorption and intestinal inflammation (loss of nutrients), anemia (decreased hemoglobin
causing decreased oxygenation), and the chronicity of symptoms.” Id. Anemia is caused by iron
deficiency and blood loss. Id. Blood loss from the intestine is “usually related to a more
prolonged chronic anemia.” Id. at 6.

Many of those who have celiac disease have no significant symptoms. Resp. Ex. T at 4.
Injury to the small intestine may develop slowly, and symptoms can be variable, and thus, it may
take years for patients to obtain testing and diagnosis. Id. Dr. Liacouras stated that it is
suspected that up to 20% of those who have the illness do not get diagnosed. Id.

Dr. Liacouras agreed that celiac disease is associated with autoimmune illnesses,
including “arthritis, psoriatic skin disorders, autoimmune thyroid diseases, inflammatory bowel
disease[,] and type 1 diabetes mellitus.” Resp. Ex. T at 5. Important risk factors include heredity
and genetics. Id. For example, the risk is increased in a person whose first-degree relatives have

78
“[T]he toxic fractions in gluten are a mixture of alcohol-soluble proteins called gliadins, which
are rich in glutamine and proline residues that even the healthy human intestine cannot fully
digest.” Resp. Ex. F at 2 (Stefano Guandalini & Asaad Assiri, Celiac Disease: A Review, 168
JAMA Pediatrics 272 (2014)).
79
Prolamins are “globular proteins found mainly in cereals; they are soluble in 70–80 per cent
alcohol but insoluble in water and absolute alcohol and contain high levels of glutamic acid and
proline. Examples are gliadin (found in wheat and rye) and zein (found in corn).” Prolamin,
Dorland’s Med. Dictionary Online, https://www.dorlandsonline.com/dorland/definition?id=
41164 (last visited Feb. 23, 2023).
80
For a discussion of the genetic predispositions, see Resp. Ex. F.
81
Riccardo Troncone & Salvatore Auricchio, Celiac Disease, in Pediatric Gastrointestinal &
Liver Disease 395 (Robert Wyllie et al. eds., 5th ed. 2016).
82
Lee A. Mancini et al., Celiac Disease and the Athlete, 10 Current Sports Med. Reps. 105
(2011).

28
an autoimmune illness. Id. The risk is also increased in patients with Hashimoto thyroiditis and
type 1 diabetes mellitus. Id.

a. Althen Prong One

Dr. Liacouras agreed that Petitioner has celiac disease but disagreed that it was caused by
her HPV vaccinations. Resp. Ex. T at 4. He provided several reasons for his opinions.

First, he explained that safety studies do not show a causal association between the HPV
vaccine and celiac disease. Resp. Ex. T at 6. He referenced several studies in support of this
opinion. The first is by Angelo et al., 83 and it was a post-licensure safety review of adverse drug
reaction reports referred to GlaxoSmithKline, the manufacturer of the HPV-16/18 vaccine
containing the alum adjuvant AS04, 84 from the United Kingdom, Netherlands, Spain, Italy, and
Japan from 2007 to 2011. Resp. Ex. T, Tab 1 at 1-2. The most common adverse reactions
reported were injection site pain, fever, headache, nausea, dizziness, injection site swelling,
malaise, pallor, myalgia, and fainting. Id. at 2 tbl.1. Regarding immune-mediated diseases, the
most common illnesses reported were Bell’s palsy (VII cranial nerve palsy) and Guillain-Barré
syndrome. Id. at 4 tbl.3. After analysis, the rate of these two conditions was determined to be
equal to or lower than expected background rates. Id. at 4, 5 tbl.4, 6 tbl.5.

He next cited Lehtinen et al., a study of approximately 30,000 adolescents who received
the HPV-16/18 vaccine (with alum containing adjuvant AS04) or hepatitis B vaccine (control
group) between 2007 and 2010. Resp. Ex. T, Tab 13 at 2. Their interim results found the most
common new onset autoimmune conditions reported after vaccination included ulcerative colitis,
juvenile onset arthritis, celiac disease, diabetes, and Crohn’s disease. Id. at 1. However, there
was no increase in these conditions observed in the HPV-16/18 vaccine recipients as compared
to the hepatitis B vaccine recipients. Id. The final results revealed consistent findings. Resp.
Ex. V, Tab 9. 85

Similar findings were reported by Medina et al., 86 who compared reports of adverse
events between adolescents who received the HPV-16/18 vaccine (with alum containing
adjuvant AS04) and those who received the hepatitis A vaccine (control group) between 2004

83
Maria-Genalin Angelo et al., Post-Licensure Safety Surveillance for Human Papillomavirus-
16/18-AS04-Adjuvanted Vaccine: More Than 4 Years of Experience, 23 Pharmacoepidemiology
& Drug Safety 456 (2014).
84
This is not the same adjuvant in the vaccine administered to Petitioner. See Pet. Ex. 349.
85
Dan Bi et al., Safety of the AS04-Adjuvanted Human Papillomavirus (HPV)-16/18 Vaccine in
Adolescents Aged 12-15 Years: End-of-Study Results from a Community-Randomized Study up
to 6.5 Years, 16 Hum. Vaccines & Immunotherapeutics 1392 (2020).
86
Doris M. Rivera Medina et al., Safety and Immunogenicity of the HPV-16/18 AS04-
Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls, 26 J. Adolescent
Health 414 (2010).

29
and 2005 in 12 different countries. Resp. Ex. T, Tab 15 at 1-2. “The incidence of unsolicited
symptoms, new onset of chronic diseases, and medically significant conditions was similar
between groups.” Id. at 1. The most common new onset chronic illnesses reported were
“allergic rhinitis, asthma, hypersensitivity, and chronic urticaria, reported at similar incidences in
both groups.” Id. at 5.

A large population-based French study by Miranda et al. 87 examined the risk of
autoimmune illnesses after the HPV vaccine. Resp. Ex. V, Tab 8 at 1. A total of 842,120 girls
received the HPV vaccine (including Gardasil). Id. at 1, 3. There was no increased incidence of
celiac disease after vaccination. Id. at 4, 4 tbl.3.

In addition to citing the studies above that failed to show a causal relationship between
the HPV vaccine and celiac disease, Dr. Liacouras observed that Petitioner’s expert, Dr. Lerner,
agreed that there are no supportive studies. Resp. Ex. V at 1. Dr. Liacouras noted Dr. Lerner,
Petitioner’s gastroenterology expert, “agreed that there are no statistically significant studies that
demonstrate a causal relationship between the HPV vaccine and the development of celiac
disease” when he stated the studies “found [celiac disease] incidence to be increased, but not
significant statistically.” Id. (quoting Pet. Ex. 150 at 8).

Next, Dr. Liacouras addressed Petitioner’s experts’ opinions related to ASCA. He opined
that there is no causal relationship between ASCA and celiac disease. Resp. Ex. T at 7.
Although Dr. Liacouras agreed that ASCA have been found in celiac patients, the autoantibodies
are also present in “many other inflammatory and autoimmune diseases.” Id. In patients with
gastrointestinal illnesses, “ASCA appear[] to be the end result of an intestinal permeability
disorder and not the cause of the disease process.” Id. And when ASCA are present, they
usually disappear after a gluten-free diet is instituted. Id.

Dr. Liacouras cited a paper by Kotze et al., 88 who examined the finding of ASCA in
patients with Crohn’s and celiac disease. Resp. Ex. T, Tab 12 at 1. They defined Crohn’s
disease as “a chronic inflammatory bowel disorder of uncertain etiology [with a] clinical course
[] characterized by relapsing and remitting chronic intestinal inflammation.” Id. The authors
explained that “the cause of ASCA positivity is [] unknown and some authors have considered
antibody formation as a consequence of increased mucosal permeability.” Id. They also
described ASCA found in patients with celiac disease at time of diagnosis that disappear after a

87
Sara Miranda et al., Human Papillomavirus Vaccination and Risk of Autoimmune Diseases: A
Large Cohort Study of Over 2 Million Young Girls in France, 35 Vaccine 4761 (2017).
88
Lorete Maria da Silva Kotze et al., Antibodies Anti-Saccharomyces Cerevisiae (ASCA) Do
Not Differentiate Crohn’s Disease from Celiac Disease, 47 Arquivos Gastroenterologia 242
(2010).

30
gluten-free diet is initiated. 89 Id. at 1-3. They concluded that ASCA may be a marker of the
integrity of the intestinal mucosa. Id. at 2-3.

b. Althen Prong Two

Dr. Liacouras opined that celiac disease was the cause of Petitioner’s symptoms during
the time frame in question, but that her celiac disease was not caused by her HPV vaccination.
Resp. Ex. T at 4, 8. He explained that Petitioner had a family history of autoimmune illnesses,
and “individuals who develop celiac disease frequently manifest a family history of other
autoimmune disorders.” Id. at 8.

c. Althen Prong Three

Regarding onset, Dr. Liacouras opines that “more likely than not, [] [Petitioner] began to
develop celiac disease before the Summer of 2011[,] and that the majority of the symptoms that
[Petitioner] initially reported beginning in the Summer and Fall of 2011 were attribut[able] to her
celiac disease.” Resp. Ex. T at 4.

As a frame of reference, Dr. Liacouras summarized the relevant facts. In January 2012,
when Petitioner was diagnosed with celiac disease, she had “severe iron deficiency anemia
(decreased MCV, serum iron[,] and ferritin).” Resp. Ex. T at 7. The prior Summer (2011),
approximately five or six months before her diagnosis, “[she] began to experience fatigue.” Id.
Petitioner reported “shortness of breath and weak legs in early September 2011.” 90 Id. Dr.
Liacouras explained that these symptoms (fatigue, shortness of breath, and weak legs) are
“typical for chronic iron deficiency anemia and malabsorption and indicate that [Petitioner’s]
celiac disease began prior to these symptoms.” Id. “Specifically, fatigue is a common feature of
celiac disease and is almost always related to anemia.” Id. Moreover, “[t]he development of
iron deficiency amenia and fatigue is not an acute manifestation but instead is a chronic process.”
Id. He opined that Petitioner’s fatigue predated her first HPV vaccination on August 30, 2011
and thus, the onset of her celiac disease occurred prior to vaccination. Id.

89
Papp et al. reported that “[t]he presence of anti-glycan antibodies [including ASCA] in [celiac
disease] seems to be secondary to the impaired small bowel mucosa which can lead to increased
antigen presentation.” Resp. Ex. T, Tab 17 at 1 (Maria Papp et al., Anti-Microbial Antibodies in
Celiac Disease: Trick or Treat?, 15 World J. Gastroenterology 3891 (2009)). The antibodies
disappear “after strict adherence to long-term [gluten-free diet].” Id. at 7.
90
In her affidavit, Petitioner averred that at a cross-country meet on September 10, 2011, she had
pain in her legs, was weak, and had difficulty breathing. Pet. Ex. 60 at ¶ 11. Petitioner’s mother
also averred that Petitioner had shortness of breath and weak legs on the same day, September
10, 2011. Pet. Ex. 61 at ¶ 6.

31
To support his opinions as to disease onset, Dr. Liacouras referenced several articles that
discuss the development of symptoms associated with celiac disease. The first, by Fuchs et al., 91
discussed “factors associated with long diagnostic delay in celiac disease” in a study of 825
adults with the illness. Resp. Ex. T, Tab 10 at 1. Of the total, “261 patients had diagnostic delay
of [greater than] 10 years.” Id. at 2. “Female gender, neurological or musculoskeletal
disorders[,] and presence of diarrhea, abdominal pain, and malabsorption were associated with
prolonged delay” in diagnosis. Id. at 1. The majority (559 or 68%) of the 825 patients had
gastrointestinal symptoms before diagnosis. Id. at 3. The authors found it “surprising that one of
the most characteristic and classic signs of celiac disease, malabsorption, increased the risk for
long delay.” Id. at 5.

Similarly, Norström et al. 92 studied 1,031 adult patients with celiac disease and found
“[t]he mean delay from the first symptoms . . . to diagnosis was 9.7 years and the median delay
was 4 years.” Resp. Ex. T, Tab 16 at 1, 3. Cranney et al. 93 also studied the “length and nature of
the diagnostic process” in 2,681 patients with celiac disease. Resp. Ex. T, Tab 5, at 1-2. Sixty-
eight percent reported extreme weakness/tiredness and 66% had anemia prior to diagnosis. Id. at
4 tbl.1. “The mean delay in diagnosis after onset of symptoms was 11.7 years” with a “median
delay” of five years. Id. at 4.

For patients who present with anemia, Dr. Liacouras cited Paez et al., 94 who reported “a
mean delay in the diagnosis of celiac disease of 3.5 years in patients who present with
nongastrointestinal symptoms.” Resp. Ex. V, Tab 3 at 2. Nongastrointestinal symptoms include
fatigue and anemia. Id. Bottaro et al. 95 reported that “iron-deficiency anemia appeared to be the
most frequent extraintestinal marker of [celiac disease].” Resp. Ex V, Tab 4 at 3. Dr. Liacouras
also cited a case report by Dina et al. 96 that described a 38-year-old female who had a history of
anemia for seven years before diagnosis. Resp. Ex. T, Tab 8 at 1. The authors noted that “[i]ron
deficiency anemia is [] the most frequent laboratory manifestation of celiac disease.” Id. at 3.

91
Valma Fuchs et al., Factors Associated with Long Diagnostic Delay in Celiac Disease, 49
Scandinavian J. Gastroenterology 1304 (2014).
92
Fredrik Norström et al., Delay to Celiac Disease Diagnosis and Its Implications for Health-
Related Quality of Life, 11 BMC Gastroenterology 1 (2011).
93
Ann Cranney et al., The Canadian Celiac Health Survey, 52 Digestive Disease & Scis. 1087
(2007).
94
Marco A. Paez et al., Delay in Diagnosis of Celiac Disease in Patients Without
Gastrointestinal Complaints, 130 Am. J. Med. 1318 (2017).
95
G. Bottaro et al., The Clinical Pattern of Subclinical/Silent Celiac Disease: An Analysis on
1026 Consecutive Cases, 94 Am. J. Gastroenterology 691 (1999).
96
I. Dina et al., Long-Standing Iron-Deficiency Anemia in an Atypical Celiac Disease—A Case
Report, 7 J. Med. & Life 99 (2014).

32
Given Petitioner’s presentation characterized by fatigue and anemia, and the findings of
the studies cited above, Dr. Liacouras concluded that “it is more likely tha[n] not that [Petitioner]
began to develop celiac disease well before the Summer of 2011.” Resp. Ex. T at 7.

Further, Dr. Liacouras opined that the symptoms that Petitioner reported “as early as
September 10, 2011[] occurred much too quickly to be associated with the possibility of HPV
induced celiac disease from a vaccine administered on August 30, 2011” because “[t]he
symptoms of celiac disease take months or years to manifest.” Resp. Ex. T at 7. Dr. Liacouras
opined that Petitioner’s onset occurred between September 10 to 17, 2011, when she complained
of shortness of breath and weak legs. Id. at 1; Resp. Ex. V at 2. He opined that onset was too
soon after vaccination to attribute the illness to the HPV vaccine because these symptoms
“would not occur within a few days of first developing the intestinal abnormalities of celiac
disease.” Resp. Ex. V at 2. The symptoms of celiac disease relate to “iron deficiency anemia or
severe chronic intestinal inflammation” and these conditions take “a significant amount of time
to occur and develop after the beginning stages of celiac disease.” Id.

To support his opinion, Dr. Liacouras cited a review paper by Stein et al., 97 who reported
that 32%-69% of patients with celiac disease have amenia, and approximately 80% of celiac
patients with anemia have iron deficiency. Resp. Ex. V, Tab 1, at 3 tbl.1, 6. The most prominent
cause of anemia is abnormal absorption of iron, along with bleeding and inflammation of the
intestine. Id. at 3 tbl.1. Anemia is defined “as a hemoglobin [] level < 12 g/dL in women.” Id.
at 2. Iron deficiency is present when “serum ferritin levels [are] below 15-100 ng/mL . . . and
transferrin saturation [] [is] below 16%-20%.” Id.

“A normal hemoglobin in a teenage female is approximately 12.” Resp. Ex. V at 3. Dr.
Liacouras opined that it would take “at least” six to 12 months for a patient with “undiagnosed
celiac disease” to develop severe anemia (hemoglobin of 8.7). Id. He cited two papers that
support his opinion. The first is a treatise on iron deficiency anemia by Braunstein, 98 who
described the stages of iron deficiency. Resp. Ex. V, Tab 5. “In the first stage, iron requirement
exceeds intake, causing progressive depletion of bone marrow iron stores.” Id. at 2. “During
later stages, deficiency impairs [red blood cell] synthesis, ultimately causing anemia.” Id.
Anemia is usually caused by blood loss and less commonly, malabsorption. Id. at 1. When
anemia is discovered, “occult blood loss should be suspected until proven otherwise.” Id.
Symptoms of iron deficiency are “due to anemia” and include “fatigue, loss of stamina, shortness
of breath, weakness, dizziness, and pallor.” Id. at 3.

More specifically, each of Braunstein’s five stages of iron deficiency are described
below.

97
Jürgen Stein et al., Anemia and Iron Deficiency in Gastrointestinal and Liver Conditions, 22
World J. Gastroenterology 7908 (2016).
98
Evan M. Braunstein, Iron Deficiency Anemia, Merck Manual,
https://www.merckmanuals.com/professional/hematology-and-oncology/anemias-caused-by-
deficient-erythropoiesis/iron-deficiency-anemia (last visited Dec. 16, 2019).

33
Stage 1 is characterized by decreased bone marrow iron stores;
hemoglobin [] and serum iron remain normal, but the serum ferritin level falls to
< 20 ng/ml. The compensatory increase in iron absorption causes an increase in
iron-binding capacity (transferrin level).

During stage 2, erythropoiesis is impaired. Although the transferrin level
is increased, the serum iron level decreases; transferrin saturation decreases.
Erythropoiesis is impaired when serum iron falls to < 50 μg/dl (< 9 μmol/L) and
transferrin saturation to < 16%. The serum transferrin receptor level rises (> 8.5
mg/L).

During stage 3, anemia with normal-appearing [red blood cells] and
indices develops.

During stage 4, microcytosis and then hypochromia develop.

During stage 5, iron deficiency affects tissues, resulting in symptoms and
signs.

Resp. Ex. V, Tab 5 at 5 (emphasis omitted).

Dr. Liacouras also cited a diagram illustrating how iron deficiency anemia effects
hemoglobin over time in a patient with severe anemia.

Resp. Ex. V, Tab 6 at 4 fig.1. 99

Lastly, Dr. Liacouras disagreed with Dr. Lerner’s opinion that if Petitioner had anemia
prior to August 2011, she would have presented with a “much more severe symptomatology,
clinical signs[,] and morbidity.” Resp. Ex. V at 3 (quoting Pet. Ex. 150 at 5). Dr. Liacouras

99
Amy Zhu et al., Evaluation and Treatment of Iron Deficiency Anemia: A Gastroenterological
Perspective, 55 Digestive Diseases & Scis. 548 (2010).

34
opined that a study from Repo et al. 100 found “patients with celiac disease and anemia do not
necessarily have more severe clinical symptoms.” Id. at 4. Repo et al. studied the incidence of
anemia and iron deficiency in 102 children with “potential” celiac disease as well as those who
had already developed “mucosal atrophy” and found that “anemia and iron deficiency . . . may []
be present in children with normal villous morphology.” Resp. Ex. V, Tab 7 at 1-2. “The main
finding . . . was that, even if more common in children with severe mucosal atrophy, celiac
disease-associated anemia and iron deficiency are a continuum and may appear even before
morphological villous damage.” Id. at 5. Although anemia was seen in almost two-thirds (63%)
of children with total villous atrophy, it was also present in one-fifth (22%) of children with
partial or subtotal villous atrophy. Id. at 1.

Further, Dr. Liacouras observed that Petitioner “had no visible gastrointestinal bleeding;
instead, she had [three] positive hemoccult tests which suggest a chronic slow loss of blood and
iron, not an acute, rapid [gastrointestinal] blood and iron loss.” Resp. Ex. V at 3. In conclusion,
Dr. Liacouras opined that like other celiac patients, it is “very likely” that Petitioner’s celiac
disease caused her symptoms in the Summer of 2011, and her symptoms “very likely” began
many months before that, but that her diagnosis was delayed until January 2012. Id. at 4-5.

D. Respondent’s Expert, Dr. Eric Lancaster 101

1. Background and Qualifications

Dr. Lancaster obtained his M.D. and Ph.D. from the University of Maryland before
completing an internship, neurology residency, and neuromuscular fellowship at the University
of Pennsylvania. Resp. Ex. A, Tab 1 at 1. Dr. Lancaster is board certified in neurology,
electromyography, and neuromuscular medicine. Id. at 2. He has worked as an Assistant
Professor of Neurology at the University of Pennsylvania since 2013. Id. at 1. Dr. Lancaster has
authored or co-authored over 20 peer-reviewed publications. Id. at 3-4. His clinic is “focused on
autoimmune neurological diseases.” Resp. Ex. A at 1.

2. Opinion

Dr. Lancaster did not offer opinions related to the appropriateness of Petitioner’s
diagnosis of celiac disease and deferred to Dr. Liacouras on that subject. Resp. Ex. W at 3. The

100
Marleena Repo et al., Amenia and Iron Deficiency in Children with Potential Celiac Disease,
64 J. Pediatric Gastroenterology & Nutrition 56 (2017).
101
Dr. Lancaster filed five expert reports. Resp. Exs. A-C, E, W. The first three reports
addressed opinions of Dr. Blitshyten, Petitioner’s initial expert. Petitioner no longer offers Dr.
Blitshyten as an expert, and therefore, the earlier reports by Dr. Lancaster addressing her
opinions are not discussed herein. Only Dr. Lancaster’s expert report identified as Respondent’s
Exhibit W is discussed here. Further, to the extent that this expert report covers subject matter
outside the scope of the issues identified in the Joint Submission, that subject matter is not
addressed. Therefore, Dr. Lancaster’s opinions about POTS, CFS, and small fiber neuropathy
are not discussed.

35
focus of his opinions was on the immune mechanisms proposed by Petitioner’s expert, Dr.
Shoenfeld. Id. at 1.

Regarding molecular mimicry, Dr. Lancaster opined that Dr. Shoenfeld relied on “low-
level homology between [human] proteins and a vaccine protein to argue that molecular mimicry
is a plausible mechanism.” Resp. Ex. W at 8. Dr. Lancaster identified a fundamental problem
with this approach: that such homologies can occur by chance. Id.

Dr. Lancaster explained that to some extent, “[l]ow-level homology between large
proteins will occur by pure chance.” Resp. Ex. W at 8. “There are only 20 amino acids that
form the basic linear structure of proteins . . . [s]o proteins with hundreds or thousands of amino
acids will inevitably share short runs of identical amino acid sequences with other proteins by
random chance.” Id. He cited a paper by Silvanovich et al., 102 who analyzed short amino acid
sequence matches (eight or less amino acids) to determine the potential for cross-reactivity
between a “protein of interest and a known allergen.” Id. at 1. They reported that “simply
searching matches of short peptide with known allergens adds little value to assess protein for
allergenic potential” as findings could be a “product of chance.” Id. at 1, 7.

Regarding Petitioner’s theory based on the alum adjuvant, Dr. Lancaster cited a paper by
Ameratunga et al., 103 in which the authors concluded that “[c]urrent data do not support
causation of ASIA.” Resp. Ex. W, Tab 10 at 1. The authors identified a number of problems
with the proposed illness, including the broad and non-specific diagnostic criteria, which include
fever, autoimmunity, and chronic fatigue. Id. at 2. They also explained that “[t]he strongest
argument against the existence of ASIA caused by [alum]-containing vaccine adjuvants is the
decreased incidence of autoimmune diseases in patients receiving [alum]-containing allergen-
specific [immunotherapy]” reported in a large study from Denmark. Id. at 3 (emphasis omitted).

VII. DISCUSSION

A. Standards for Adjudication

The Vaccine Act was established to compensate vaccine-related injuries and deaths. §
10(a). “Congress designed the Vaccine Program to supplement the state law civil tort system as
a simple, fair and expeditious means for compensating vaccine-related injured persons. The
Program was established to award ‘vaccine-injured persons quickly, easily, and with certainty
and generosity.’” Rooks v. Sec’y of Health & Hum. Servs., 35 Fed. Cl. 1, 7 (1996) (quoting
H.R. Rep. No. 908 at 3, reprinted in 1986 U.S.C.C.A.N. at 6287, 6344).

102
Andre Silvanovich et al., The Value of Short Amino Acid Sequence Matches for Prediction of
Protein Allergenicity, 90 Toxicological Scis. 252 (2006).
103
Rohan Ameratunga et al., Evidence Refuting the Existence of
Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA), 5 J. Allergy &
Clinical Immunology Practice 1551 (2017).

36
Petitioner’s burden of proof is by a preponderance of the evidence. § 13(a)(1). The
preponderance standard requires a petitioner to demonstrate that it is more likely than not that the
vaccine at issue caused the injury. Moberly v. Sec’y of Health & Hum. Servs., 592 F.3d 1315,
1322 n.2 (Fed. Cir. 2010). Proof of medical certainty is not required. Bunting v. Sec’y of Health
& Hum. Servs., 931 F.2d 867, 873 (Fed. Cir. 1991). Petitioner need not make a specific type of
evidentiary showing, i.e., “epidemiologic studies, rechallenge, the presence of pathological
markers or genetic predisposition, or general acceptance in the scientific or medical communities
to establish a logical sequence of cause and effect.” Capizzano v. Sec’y of Health & Hum.
Servs., 440 F.3d 1317, 1325 (Fed. Cir. 2006). Instead, Petitioner may satisfy her burden by
presenting circumstantial evidence and reliable medical opinions. Id. at 1325-26.

In particular, Petitioner must prove that the vaccine was “not only [the] but-for cause of
the injury but also a substantial factor in bringing about the injury.” Moberly, 592 F.3d at 1321
(quoting Shyface v. Sec’y of Health & Hum. Servs., 165 F.3d 1344, 1352-53 (Fed. Cir. 1999));
see also Pafford v. Sec’y of Health & Hum. Servs., 451 F.3d 1352, 1355 (Fed. Cir. 2006). The
received vaccine, however, need not be the predominant cause of the injury. Shyface, 165 F.3d
at 1351. A petitioner who satisfies this burden is entitled to compensation unless Respondent
can prove, by a preponderance of the evidence, that the vaccinee’s injury is “due to factors
unrelated to the administration of the vaccine.” § 13(a)(1)(B). However, if a petitioner fails to
establish a prima facie case, the burden does not shift. Bradley v. Sec’y of Health & Hum.
Servs., 991 F.2d 1570, 1575 (Fed. Cir. 1993).

“Regardless of whether the burden ever shifts to the [R]espondent, the special master
may consider the evidence presented by the [R]espondent in determining whether the [P]etitioner
has established a prima facie case.” Flores v. Sec’y of Health & Hum. Servs., 115 Fed. Cl. 157,
162-63 (2014); see also Stone v. Sec’y of Health & Hum. Servs., 676 F.3d 1373, 1379 (Fed. Cir.
2012) (“[E]vidence of other possible sources of injury can be relevant not only to the ‘factors
unrelated’ defense, but also to whether a prima facie showing has been made that the vaccine
was a substantial factor in causing the injury in question.”); de Bazan v. Sec’y of Health & Hum.
Servs., 539 F.3d 1347, 1353 (Fed. Cir. 2008) (“The government, like any defendant, is permitted
to offer evidence to demonstrate the inadequacy of the [P]etitioner’s evidence on a requisite
element of the [P]etitioner’s case-in-chief.”); Pafford, 451 F.3d at 1358-59 (“[T]he presence of
multiple potential causative agents makes it difficult to attribute ‘but for’ causation to the
vaccination. . . . [T]he Special Master properly introduced the presence of the other unrelated
contemporaneous events as just as likely to have been the triggering event as the vaccinations.”).

B. Factual Issues

A petitioner must prove, by a preponderance of the evidence, the factual circumstances
surrounding her claim. § 13(a)(1)(A). To resolve factual issues, the special master must weigh
the evidence presented, which may include contemporaneous medical records and testimony.
See Burns v. Sec’y of Health & Hum. Servs., 3 F.3d 415, 417 (Fed. Cir. 1993) (explaining that a
special master must decide what weight to give evidence including oral testimony and
contemporaneous medical records). Contemporaneous medical records, “in general, warrant
consideration as trustworthy evidence.” Cucuras v. Sec’y of Health & Hum. Servs., 993 F.2d
1525, 1528 (Fed. Cir. 1993). But see Kirby v. Sec’y of Health & Hum. Servs., 997 F.3d 1378,

37
1382 (Fed. Cir. 2021) (rejecting the presumption that “medical records are accurate and complete
as to all the patient’s physical conditions”); Shapiro v. Sec’y of Health & Hum. Servs., 101 Fed.
Cl. 532, 538 (2011) (“[T]he absence of a reference to a condition or circumstance is much less
significant than a reference which negates the existence of the condition or circumstance.”
(quoting Murphy v. Sec’y of Health & Hum. Servs., 23 Cl. Ct. 726, 733 (1991), aff’d per curiam,
968 F.2d 1226 (Fed. Cir. 1992))), recons. den’d after remand, 105 Fed. Cl. 353 (2012), aff’d
mem., 503 F. App’x 952 (Fed. Cir. 2013).

There are situations in which compelling testimony may be more persuasive than written
records, such as where records are deemed to be incomplete or inaccurate. Campbell v. Sec’y of
Health & Hum. Servs., 69 Fed. Cl. 775, 779 (2006) (“[L]ike any norm based upon common
sense and experience, this rule should not be treated as an absolute and must yield where the
factual predicates for its application are weak or lacking.”); Lowrie v. Sec’y of Health & Hum.
Servs., No. 03-1585V, 2005 WL 6117475, at *19 (Fed. Cl. Spec. Mstr. Dec. 12, 2005)
(“[W]ritten records which are, themselves, inconsistent, should be accorded less deference than
those which are internally consistent.” (quoting Murphy, 23 Cl. Ct. at 733)). Ultimately, a
determination regarding a witness’s credibility is needed when determining the weight that such
testimony should be afforded. Andreu v. Sec’y of Health & Hum. Servs., 569 F.3d 1367, 1379
(Fed. Cir. 2009); Bradley, 991 F.2d at 1575.

Despite the weight afforded to medical records, special masters are not bound rigidly by
those records in determining onset of a petitioner’s symptoms. Valenzuela v. Sec’y of Health &
Hum. Servs., No. 90-1002V, 1991 WL 182241, at *3 (Fed. Cl. Spec. Mstr. Aug. 30, 1991); see
also Eng v. Sec’y of Health & Hum. Servs., No. 90-1754V, 1994 WL 67704, at *3 (Fed. Cl.
Spec. Mstr. Feb. 18, 1994) (“[Section 13(b)(2)] must be construed so as to give effect also to §
13(b)(1) which directs the special master or court to consider the medical records (reports,
diagnosis, conclusions, medical judgment, test reports, etc.), but does not require the special
master or court to be bound by them.” (emphasis omitted)).

C. Causation

To receive compensation under the Program, Petitioner must prove either: (1) that she
suffered a “Table Injury”—i.e., an injury listed on the Vaccine Injury Table—corresponding to a
vaccine that she received, or (2) that she suffered an injury that was caused by a vaccination. See
§§ 11(c)(1), 13(a)(1)(A); Capizzano, 440 F.3d at 1319-20. Petitioner must show that the vaccine
was “not only a but-for cause of the injury but also a substantial factor in bringing about the
injury.” Moberly, 592 F.3d at 1321 (quoting Shyface, 165 F.3d at 1352-53).

Because Petitioner does not allege that she suffered a Table injury, she must prove that a
vaccine caused her injury. To do so, she must establish, by preponderant evidence: (1) a medical
theory causally connecting the vaccine and her injury (“Althen Prong One”); (2) a logical
sequence of cause and effect showing that the vaccine was the reason for her injury (“Althen
Prong Two”); and (3) a showing of a proximate temporal relationship between the vaccine and
her injury (“Althen Prong Three”). § 13(a)(1); Althen, 418 F.3d at 1278.

38
The causation theory must relate to the injury alleged. Petitioner must provide a sound
and reliable medical or scientific explanation that pertains specifically to this case, although the
explanation need only be “legally probable, not medically or scientifically certain.” Knudsen v.
Sec’y of Health & Hum. Servs., 35 F.3d 543, 543, 548-49 (Fed. Cir. 1994). Petitioner cannot
establish entitlement to compensation based solely on her assertions; rather, a vaccine claim must
be supported either by medical records or by the opinion of a medical doctor. § 13(a)(1). In
determining whether Petitioner is entitled to compensation, the special master shall consider all
materials in the record, including “any . . . conclusion, [or] medical judgment . . . which is
contained in the record regarding . . . causation.” § 13(b)(1)(A). The undersigned must weigh
the submitted evidence and the testimony of the parties’ proffered experts and rule in Petitioner’s
favor when the evidence weighs in her favor. See Moberly, 592 F.3d at 1325-26 (“Finders of
fact are entitled—indeed, expected—to make determinations as to the reliability of the evidence
presented to them and, if appropriate, as to the credibility of the persons presenting that
evidence.”); Althen, 418 F.3d at 1280 (noting that “close calls” are resolved in Petitioner’s
favor).

Testimony that merely expresses the possibility—not the probability—is insufficient, by
itself, to substantiate a claim that such an injury occurred. See Waterman v. Sec’y of Health &
Hum. Servs., 123 Fed. Cl. 564, 573-74 (2015) (denying Petitioner’s motion for review and
noting that a possible causal link was not sufficient to meet the preponderance standard). The
Federal Circuit has made clear that the mere possibility of a link between a vaccination and a
petitioner’s injury is not sufficient to satisfy the preponderance standard. Moberly, 592 F.3d at
1322 (emphasizing that “proof of a ‘plausible’ or ‘possible’ causal link between the vaccine and
the injury” does not equate to proof of causation by a preponderance of the evidence); Boatmon
v. Sec’y of Health & Hum. Servs., 941 F.3d 1351, 1359-60 (Fed. Cir. 2019). While certainty is
by no means required, a possible mechanism does not rise to the level of preponderance.
Moberly, 592 F.3d at 1322; see also de Bazan, 539 F.3d at 1351.

D. Analysis

1. Althen Prong One: Petitioner’s Medical Theory

Under Althen Prong One, Petitioner must set forth a medical theory explaining how the
received vaccine could have caused the sustained injury. Andreu, 569 F.3d at 1375; Pafford, 451
F.3d at 1355-56. Petitioner’s theory of causation need not be medically or scientifically certain,
but it must be informed by a “sound and reliable” medical or scientific explanation. Boatmon,
941 F.3d at 1359; see also Knudsen, 35 F.3d at 548; Veryzer v. Sec’y of Health & Hum. Servs.,
98 Fed. Cl. 214, 223 (2011) (noting that special masters are bound by both § 13(b)(1) and
Vaccine Rule 8(b)(1) to consider only evidence that is both “relevant” and “reliable”). If
Petitioner relies upon a medical opinion to support her theory, the basis for the opinion and the
reliability of that basis must be considered in the determination of how much weight to afford the
offered opinion. See Broekelschen v. Sec’y of Health & Hum. Servs., 618 F.3d 1339, 1347 (Fed.
Cir. 2010) (“The special master’s decision often times is based on the credibility of the experts
and the relative persuasiveness of their competing theories.”); Perreira v. Sec’y of Health &
Hum. Servs., 33 F.3d 1375, 1377 n.6 (Fed. Cir. 1994) (stating that an “expert opinion is no better

39
than the soundness of the reasons supporting it” (citing Fehrs v. United States, 620 F.2d 255, 265
(Ct. Cl. 1980))).

The undersigned finds Petitioner has failed to prove by preponderant evidence that the
HPV vaccinations she received caused her celiac disease for the following reasons.

First, Petitioner’s experts’ opinions are not supported by foundational evidence, are not
developed, and are overall conclusory. Starting with Dr. Lerner, he proposes a mechanism based
on the alum adjuvant. But he never explains how alum triggers an immune response, and how
that immune response causes celiac disease. Similarly, he opines that alum is involved in the
“autoimmunogenesis” of intestinal inflammation and Crohn’s disease, but again he does not
explain the process for how that happens. The articles he cites state that the etiology of Crohn’s
disease is not known. The trigger of celiac disease is known to be gluten. Dr. Lerner does not
recognize differences between the two diseases or explain how causal theories that may apply

[Text truncated at 120,000 characters. The full text is on the page linked above.]

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/9387491. Public record. Not legal advice.